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Abstract 
 
 
 
Abstract 
Genomic instability is a characteristic of almost all human cancers. Most commonly, it may 
result from gross chromosomal changes, such as translocations, deletions and amplifications, 
which lead to chromosomal instability. Such chromosomal abnormalities are the consequence of 
DNA double-strand breaks (DSBs) which result from stalled replication forks formed within 
common fragile sites (CFSs). Based on several studies it is proposed that CFSs are prone to 
deletions and translocations in cancer cells and also instability-induced alterations in some CFS 
genes contribute to cancer development.  
The short arm of chromosome 9 has been found to be involved in several types of tumors. 
Translocations and loss of heterozygosity (LOH) on 9p have been frequently reported in various 
cancers. In this thesis the overall rearrangement events on entire 9p and the impact of two 9p-
located CFSs and their associated genes (FRA9G/CNTLN and FRA9C/LINGO2) on instability of 
the region were investigated. The analysis was performed on four tumor model types using high 
resolution array-based comparative genomic hybridization (CGH). 
A high percentage of the cell lines showed rearrangements on their 9p arm. Overall, three 
regions of breakpoint clusters were identified on 9p including the two CFSs (FRA9G/CNTLN, 
FRA9C/LINGO2) and the CDKN2A locus. Different patterns of alterations and distribution of 
breakpoints were observed in each tumor type. FRA9G/CNTLN and FRA9C/LINGO2 were 
frequently involved in genomic alterations of 9p, particulary in glioma/glioblastoma and 
neuroblastoma cells. Additionally, in three tumor types (glioma/glioblastoma, neuroblastoma 
and colon cancers) a significant number of breakages occurred in a region flanked by the two 
CFSs. Moreover, having the advantage of high-resolution aCGH, other genes of frequently 
damage were observed, leading to suggest them as novel candidates for tumor-susceptibility 
loci. 
All these results strongly indicate the association of FRA9G/CNTLN and FRA9C/LINGO2 to 
increased genomic instability of 9p in different tumor types. One important task to be explored 
in the future will be the causes and effects of dysfunction of these newly identified genes in 
tumor development. 
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Zusammenfassung 
 
 
 
Zusammenfassung 
Genomische Instabilität tritt charakteristischerweise bei fast allen Krebsarten des Menschen auf. 
In den meisten Fällen liegen ihr wahrscheinlich schwerwiegende chromosomale Veränderungen, 
wie beispielsweise Translokationen, Deletionen und Amplifikationen zugrunde. Solche 
chromosomalen Anomalitäten entstehen aufgrund von DNA Doppelstrangbrüchen (DSBs), die 
wiederum während einer abnormen Zellteilung durch Verzögerung der Replikationsgabel 
innerhalb von bestimmten chromosomalen Regionen, den sogenannten “Common Fragile Sites“ 
(CFSs), entstehen. Studien haben gezeigt, dass CFSs in Krebszellen zu Deletionen und 
Translokationen neigen und außerdem Veränderungen in CFS Genen, die durch genomische 
Instabilität ausgelöst worden sind, zur Krebsentstehung beitragen. 
Der kurze Arm von Chromosom 9 ist bei einigen Tumorarten von solchen Abweichungen 
betroffen, beispielsweise wird bei vielen verschiedenen Krebsarten häufig von Translokationen 
und Verlust der Heterozygosität (Loss of Heterozygosity, LOH) auf 9p berichtet. 
Diese Dissertation untersucht genetische Abweichungen, die auf dem gesamten 
Chromosomenarm 9p auftreten, sowie den Einfluss der zwei auf 9p gelegenen CFSs und deren 
assoziierte Gene (FRA9G/CNTLN und FRA9C/LINGO2) auf genomische Instabilität innerhalb 
dieser Region. Zu diesem Zweck wurden vier Tumormodelle mittels hochauflösender array-
basierter komparativer genomischer Hybridisierung (CGH) analysiert. Ein hoher Prozentsatz der 
untersuchten Zelllinien zeigte Veränderungen des Chromosomenarms 9p auf. Insgesamt wurden 
drei Regionen zahlreicher Bruchpunkte identifiziert, einschließlich der beiden CFSs und des 
CDKN2A Locus. FRA9G/CNTLN and FRA9C/LINGO2 waren oft von genomischen 
Anomalitäten betroffen, besonders in Gliom- bzw. Glioblastom- und Neuroblastomzellen. 
Darüber hinaus wurde in drei verschiedenen Tumorarten (Gliom/Glioblastom, Neuroblastom 
und Dickdarmkrebs) eine signifikante Anzahl von Brüchen innerhalb der von den beiden CFSs 
umgebenen Region beobachtet. Die durch array CGH erreichte Hochauflösung ermöglichte 
zudem die Identifizierung weiterer häufig geschädigter Gene, die somit als neue mögliche 
Tumor-Suszeptibilitätsloci in Betracht gezogen werden können. 
Diese Ergebnisse weisen bei verschiedenen Tumorarten deutlich auf einen Zusammenhang hin 
zwischen FRA9G/CNTLN und FRA9C/LINGO2 und genomischer Instabilität im 
Chromosomenarm 9p. Wichtig bleibt künftig die Ursachen sowie die Auswirkungen der 
Dysfunktion dieser neu identifizierten Gene zu erforschen. 
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1.  Introduction 
 
1.1 Genomic instability in cancer 
 
Genetic instability is defined asa set of events that are capable of rendering unscheduled 
aberrations within the genome. This is the distinctive feature of almost all types of human 
cancers. There are various forms of instabilities which are further categorized in three major 
groups, MIN, NIN and CIN. 
Microsatellite instability (MIN, also known as MIS) is an instability of microsatellite repeat 
sequences which is caused by the expansion of a number of oligonucleotide repeats as a result of 
defects in mismatch repair pathway. There is also the NIN (NER-related instability) form of 
genomic instability which could be formed by increased frequencies of base-pair mutations and 
nuclear excision repair.  
The major form of genomic instability in human cancers, however, is called chromosomal 
instability (CIN) which refers to an accelerated rate of structural and numerical chromosomal 
alterations. These alterations result in the gain or loss of whole chromosomes as well as 
inversions, duplications, deletions and translocations of parts of a chromosome. Aneuploidy 
which is an abnormal karyotype of many cancers develops as a result of chromosomal 
instability.  
In sporadic cancers, two models are considered to explain the chromosomal instability. The first 
model is the mutator hypothesis in which the presence of CIN is attributed to the mutations in 
DNA repair genes and mitotic checkpoint genes. These genes have been linked to the repair of 
DNA double-strand breaks (DSBs) or DNA interstrand cross links. It has been shown that 
increasing spontaneous mutations in precancerous lesions drives tumor development, and that 
mutations occur in genes that primarily function to maintain genomic stability. The second 
model is the oncogene-induced DNA replication stress. According to this model, CIN in cancer 
results from the oncogene-induced collapse of replication forks, which leads to DNA DSBs and 
genomic instability. Specific genomic sites, called common fragile sites (CFSs), are sensitive to 
DNA damages resulting from replication stress.  
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1.2 Fragile sites 
 
The first description of non-random human chromosome fragility was reported in 1965 in cells 
from a woman previously irradiated (Dekaban 1965). The term fragile site was first coined in 
1970 to describe recurrent chromosome breaks on the long arm of chromosome 16 (Magenis et 
al. 1970). The significance of fragile site regions and their expression for the human genetics 
however was realized after the identification of the fragile X syndrome, which is the most 
common inherited form of mental retardation (Jacobs et al. 1980). Fragile sites are defined as 
heritable specific loci in mammalian chromosomes that exhibit gaps and breaks when 
chromosomes are exposed to specific cell culture conditions (Sutherland 1979; Sutherland et al. 
1980; Glover et al. 1984; Sutherland et al. 1984). To date, according to NCBI Database, more 
than 120 different fragile sites have been identified.  
Fragile sites are classified as either rare or common, according to their frequency in the 
population (Sutherland and Richards 1995). Rare fragile sites (RFSs) are presented in less than 
5% of the population, whereas common fragile sites (CFSs) are considered to be part of normal 
chromosome structure and subsequently present in all individuals. They are further subdivided 
according their specific mode of induction in vitro (Berger et al. 1985). Rare fragile sites are 
subdivided into folate sensitive and non-folate sensitive ones. Folate sensitive fragile sites are 
induced by thymidilate stress, whereas non-folate sensitive ones are obtained after exposure to 
distamycin A or to bromodexocyuridine (BrdU). Most of the common fragile sites are induced 
by aphidicolin, and the others are BrdU or 5-ayacytidine inducible. The induction of all known 
fragile sites requires induction during tissue culture, with the exception of a few cases of 
spontaneous expression in FRA16B and FRA17A.  
Since both rare and common fragile sites had been demonstrated originally under artificial 
conditions, there was concern over their presence in vivo. The cloning of rare fragile site 
FRA11B (11q23.3) within the CBL2 oncogene was the first evidence of fragile site breakage in 
vivo (Jones 1995).  
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1.2.1  Rare fragile sites 
 
Rare fragile sites are segregated in Mendelian manner and have an incidence ranging from one 
in several thousands to one in 20 individuals (Sutherland 2003). The majority of the rare fragile 
sites (24/31) are folate sensitive. Since expression of these fragile sites requires lowered levels 
of components involved in DNA synthesis, it was considered that these sites might have special 
sequence composition. In fact, normal alleles at these sites were found to consist of expanded 
CGG microsatellite repeats (Oberle et al. 1991; Nancarrow et al. 1995; Sarafidou et al. 2004; 
Winnepenninckx et al. 2007). These trinucleotide repeats have two intrinsic characteristics that 
may affect their replication dynamic and underlie a basis for their fragility. First, these 
sequences are capable of adopting unusual, non-B DNA secondary structure (Pearson and 
Sinden 1998). Such structures can perturb DNA elongation (Usdin and Woodford 1995). The 
second characteristic of CGG repeats is their low efficiency of assembly into nucleosome. It 
means that the decondensation seen as gaps at fragile sites might reflect perturbed nucleosome 
assembly at these regions (Wang 1996). 
Two non-folate rare fragile sites, FRA10B (Hewett et al. 1998) and FRA16B (Yu et al. 1997) 
have shown to comprise AT-rich minisatellite repeats and their expression is associated with 
expansion of one ore more of these repeats. The proposed mechanism for the expansion is a 
dynamic mutation process with increase of up to several kilobases of DNA. The AT-rich 
repeats, similar to CGG repeats, have the ability to form non-B DNA structures such as hairpins, 
and therefore can perturb and delay DNA replication. 
The significance of rare fragile sites in human diseases is mostly related to FRAXA (associated 
with the fragile X syndrome, the most common familial severe mental retardation) and FRAXE  
(associated with X-linked non-specific mild mental retardation). 
 
 
1.2.2   Common fragile sites 
 
Common fragile sites, in contrast to rare fragile sites, are seen in all individuals and therefore 
are considered a component of normal chromosome structure. Common fragile sites are 
typically stable in culture cells grown under normal conditions. However, under conditions that 
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obstruct DNA synthesis, they are prone to appear as cytogenetic lesions like gaps or breaks. 
Such conditions comprise folate or thymidylate stress, or presence of low doses of aphidicolin 
(Glover et al. 1984; Glover and Stein 1988). Common fragile sites fall into 3 groups. The 
majority of the CFSs (77/89) are induced by exposure to aphidicolin (APH), an inhibitor of 
DNA polymerases. The other two groups can be induced by 5-azacytidine (4/79), an inhibitor of 
the DNA methyl-transferase, or by bromodeoxyuridin (BrdU) (7/79) (Lukusa and Fryns 2008). 
The exact number of common fragile sites seems to exceed the number of identified by classical 
cytogenetic techniques, since four new CFSs, FRA4F (Rozier et al. 2004) , FRA7K (Helmrich et 
al. 2007), FRA6H and FRA13E (Fechter et al. 2007) have been revealed applying high 
resolution mapping approaches. 
To date, thirteen common fragile sites have been cloned and characterized at molecular levels in 
various ways: FRA2G, FRA3B, FRA4F, FRA6E, FRA6F, FRA7E, FRA7G, FRA7H, FRA7I, 
FRA8C, FRA9E, FRA16D and FRAXB (Schwartz et al. 2006). All are aphidicolin inducible and 
extend over at least 500 kb of genomic region (Paradee et al. 1996; Boldog et al. 1997).  
Not all fragile sites form breaks at the same frequency and some of them are more prone to form 
lesions. FRA3B (3p14.2) is the most highly inducible common fragile site, found in treated 
metaphases of most humans (Smeets 1986). FRA6E (6q26), FRA7H (7q32.3), FRA16D (16q23) 
and FRAXB (Xp22.3) are the other highly expressed CFSs in lymphocytes (Glover et al. 1984). 
With the cloning and characterization of CFSs, it is now known that their expression could be 
visible over megabases of choromosomal region. Therefore, common fragile sites seem to 
represent regions of fragility, rather than specific loci (Handt 2000).  
 
 
1.2.2.1   Genes at common fragile sites 
 
From the thirteen CFSs which have been cloned and characterized at molecular level, most of 
them either lie within or span the known genes (Smith DI 2006). FRA3B was the first fragile site 
to be cloned and mapped. The identification of homozygous deletions within the FRA3B region 
in a variety of cancer types led to the identification of the fragile histidine triade gene (FHIT) 
(Druck et al. 1997). FRA3B was found to lie within the FHIT gene (Boldog et al. 1994; Wilke et 
al. 1994; Ohta et al. 1996). FHIT has a very unusual genomic structure and contains 10 small 
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exons which span over 1.5Mb of genomic sequence, including two large introns (Ohta et al. 
1996). Greater that 99% of this gene is intronic sequences and only a small transcript, 1.2 kb, is 
encoded. There are evidences that FHIT acts as a tumor suppressor gene (Siprashvili et al. 1997; 
Zanesi et al. 2001). Fhit hydrolyzes diadenosine tetraphosphates which are produced in cells in 
response to stress (Kisselev L.L. 1998). 
Great homology has been observed between DNA sequences surrounding the human FHIT and 
mouse Fhit gene, even within intronic sequences. It was also found that mouse Fhit lies within a 
CFS in the mouse (Matsuyama et al. 2003). These observations suggest that the very large gene 
and the highly unstable chromosomal region are co-conserevd, possibly due to serving some 
function together within the cell (Smith et al. 2007). 
FRA16D, which together with FRA3B are the most active CFSs, also lies within a large gene 
WWOX. Despite its large size (1Mb), WWOX encodes a small 2.2-kb transcript and is believed 
to be a tumor suppressor gene. In response to stress, WWOX appears to be specifically 
phosphorylated and this form can bind to p53 and induce apoptosis (Chang et al. 2003). Thus 
there is potential association of FHIT and WWOX with cellular response to stress. 
FRA6E is another CFS that lies within the large Parkin (PARK2) gene which extends over 1.3 
Mb (Denison et al. 2003). Parkin has been shown to interact with a number of key neural 
proteins including synuclein (Chung et al. 2001) and its expression was down-regulated in 60% 
of primary ovarian tumors analyzed (Denison et al. 2003; Wang et al. 2004). Introduction of 
Parkin into the cells that did not express it, resulted in more sensitivity of those cells to apoptotic 
induction (Denison et al. 2003). 
GRID2 is another extremely large gene (1.46Mb) that is localized within FRA4F (4q22) region 
(Rozier et al. 2004). Recurrent deletions of subregions of band 4q22 have been described in 
human hepatocellular carcinoma, suggesting roles for GRID2 in hepatic carcinogenesis (Bluteau 
et al. 2002). 
Many of the large CFS genes are involved in neurological development (Dussault et al. 1998; 
Doughty et al. 2000; Verkerk et al. 2003; Cam et al. 2004; Lorenzetti et al. 2004).  
There is one interesting observation that so many of the large CFS genes appear to function as 
stress responders (Smith et al. 2007). One possibility underlying the mechanism for this 
function is that somehow the CFS regions are able to transduce cellular stresses into different 
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transcripts being produced from the large CFS genes. An alternative could be that the very large 
introns produce transcripts which somehow regulate the expression of the large CFS genes. 
Re and colleagues proposed that replication stress at fragile sequences is coupled with a 
modified expression of the associated fragile genes (Re et al. 2006). They suggest that fragile 
sequences, sensitive to replication stress, are not located by chance within or near fragile genes, 
but participate together with the genes to the mechanism that regulates the cellular response to 
DNA damage.  
 
 
1.2.2.2   Instability at common fragile sites 
 
1.2.2.2.1   Common fragile site instability in vitro 
 
Although CFSs are normally stable regions in cultured human cells, but under conditions that 
partially inhibit DNA synthesis, form gaps and breaks. In addition to displaying gaps and 
breaks, CFSs are hot spots for deletions and translocations (Glover and Stein 1988; Wang et al. 
1997), increased rates of sister chromatid exchange (Glover and Stein 1987; Feichtinger and 
Schmid 1989; Hirsch 1991), plasmid or vector integration (Rassool et al. 1991; Wilke et al. 
1996; Mishmar et al. 1998), interchromosomal gene amplification (Coquelle et al. 1997; 
Hellman et al. 2002) and regions of potential genome instability (Glover 1998). There are also 
reports of coincidence of viral integration sites in tumors or tumor cell lines and fragile sites 
(Popescu and DiPaolo 1989; De Braekeleer et al. 1992). 
 
 
1.2.2.2.2   Common fragile site instability in cancer 
 
All the various forms of DNA instability which have been associated with CFSs (like forming 
boundaries of amplified regions of genome, plasmid and viral DNA integration, sister chromatid 
exchange and recombination) would require DSBs as an initiating event. Therefore DSB appears 
to be a typical feature of common fragile sites. Aberrant repair of these fragile site-associated 
DSBs could eventually lead to deletions such as those that have been observed at common 
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fragile sites in various cancers (O'Keefe and Richards 2006). It has been suggested that fragile 
sites are associated with cancer development from the early stages of tumorigenesis (Gorgoulis 
et al. 2005; Halazonetis et al. 2008)  
Studies on the most frequently expressed CFSs, FRA16D and FRA3B, have provided compelling 
evidence that these regions are prone to deletions and translocation in cancer cells. Identification 
of homozygous deletions presents a novel mechanism for gene inactivation in the absence of 
mutations within a coding sequence. The relative frequency of cytogenetic appearance of CFSs 
in vitro corresponds to the relative frequency of deletions observed in cancer cell lines in vivo 
(Arlt et al. 2002; Finnis et al. 2005).  Deletion analysis of cell lines derived from a primary 
carcinoma (KM12C) and from a secondary metastasis of this same carcinoma (KM12SM) 
revealed precisely the same deletion endpoints in the region of FRA16D, despite instabilities in 
other regions of the genome (Finnis et al. 2005). Homozygous deletions of FRA16D have also 
been detected in cell lines derived from breast, lung, stomach, colon and ovary carcinomas 
(Bednarek et al. 2000; Mangelsdorf et al. 2000; Paige et al. 2000).  
When looking for genes in 16q23.2, one of the frequent sites of LOH in breast cancer, Bednarek 
et al. (Bednarek et al. 2000) found WWOX gene, which lies within FRA16D. Several recent 
studies have demonstrated a tumor suppressor function for WWOX gene (Boldog et al. 1997; 
Bednarek et al. 2001; Aqeilan et al. 2007; Salah Z 2010). Targeted inactivation of Wwox led to 
the spontaneous occurrence of osteosarcomas in juvenile Wwox−/− mice and lung papillary 
carcinoma in adult Wwox+/− mice (Aqeilan et al. 2007). Deletions of microsatellite markers 
within the FRA16D/WWOX locus are prevalent in several tumor types including breast, prostate, 
esophageal, lung, stomach, prostate, ovary and pancreatic carcinomas (Ried et al. 2000; Paige et 
al. 2001; Driouch et al. 2002; Kuroki et al. 2002; Yendamuri et al. 2003; Kuroki et al. 2004; 
Lewandowska et al. 2009).  
Several tumor-derived cell lines with transgenic deletion in FRA16D, also frequently show 
deletion in FRA3B. This could be an indicative of a common mechanism that may be causal in 
such deletion events (Finnis et al. 2005). The FHIT gene spans the FRA3B fragile site and, being 
a huge gene similar to WWOX, some homozygous deletions occur only within a large intron. 
Deletions mostly give rise to aberrant transcripts; however, FRA3B-deleted cancer cells are 
marked by an absence of the encoded FHIT protein, indicating that loss of function is the most 
likely consequence of deletion (Druck et al. 1997). Transgenic mice heterozygous for knockout 
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of the Fhit gene have increased susceptibility to mutagen-induced tumor formation (Fong et al. 
2000), and since it has been found that Fhit gene also contains a common fragile site (Glover et 
al. 1998), probably this fragile site provides the susceptible target for the second hit in the 
heterozygous knockout mice. Increased sensitivity of Fhit heterozygous transgenic mice is 
supportive for the idea that individuals with higher expression of fragile sites would be more 
sensitive to environmental mutagenesis and thus at the greater risk of any associated type of 
cancer (Richards 2001). Moreover, the overexpression of FHIT suppresses the growth of cancer 
cell lines in vitro and in vivo (Siprashvili et al. 1997). FHIT is frequently involved in biallelic 
loss and other chromosomal abnormalities in tumors (Ohta et al. 1996; Kameoka et al. 2004; 
Hassan et al. 2010). A high frequency of homozygous and heterozygous deletions within 
FRA3B region have been detected in different cancers and cancer cell lines like esophageal 
adenocarcinoma (Michael et al. 1997), gastric cancer (Lee et al. 2001), head and neck squamus 
cell carcinoma (Virgilio et al. 1996),  large B-cell lymphomas (Kameoka et al. 2004) and 
pancreatobiliary cancers ((Bloomston M 2009). 
Other CFSs and their associated genes, including FRA6E26, FRA9E13, and FRA7G (Huang et 
al. 1998; Bednarek et al. 2000), have also shown similar patterns of deletion in cancer cells. 
Therefore, considerable amount of studies are indicative of CFSs representing targets that are 
"weak links" (Huebner and Croce 2001) for genomic alterations in at least some cancer cells. 
Recurrent chromosomal translocations tend to be hallmarks of particular kinds of cancer. As 
much as 25% of the translocation breakpoints in multiple myeloma map to FRA16D region 
(Chesi et al. 1998; Krummel et al. 2000; Mangelsdorf et al. 2000; Paige et al. 2000). These 
recurrent translocations result in at least one truncated allele of WWOX in tumor cells (Bednarek 
et al. 2000; Mangelsdorf et al. 2000; Ried et al. 2000; Krummel et al. 2002). The FRA3B fragile 
site, also has been reported to be the site of the chromosome 3 breakpoint in the familial clear 
cell renal carcinoma translocation (Ohta et al. 1996). Translocations in other CFSs have also 
been reported. FRA6E and FRA6F in acute lymphpblastic and acute myeloid leukemia (Sinclair 
et al. 2005) and FRA2G in members of a family with multifocal clear renal cell carcinoma have 
shown to have translocations. In a very recent interesting study (Gandhi et al. 2010) it was 
shown that induction of breakage at fragile sites FRA10C and FRA10G under fragile site-
inducing conditions initiated and led to the generation of rearrangements in RET/PTC1 partner 
genes which lie within these fragile sites. These rearrangements then contribute to papillary 
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thyroid carcinoma (PTC) development. This is the first direct evidence demonstrating the role of 
fragile sites in cancer-specific translocations. 
While deletion breakpoints within CFSs in cancer cells are common, relatively fewer 
translocations involving CFSs have been reported. Both deletions and translocations at CFSs 
appear to inactivate associated genes rather than deregulate their expression.  
In addition to deletion and translocation, CFSs have been associated with viral integration and 
gene amplification in tumor cells. Cervical carcinoma frequently exhibit human papillomavirus 
(HPV) integration in association wit acquiring malignant phenotype (Thorland EC 2000). This 
led to identify more viral integration sites at CFSs (Popescu and DiPaolo 1989; De Braekeleer et 
al. 1992; Smith et al. 1992; Wilke et al. 1996; Thorland et al. 2003).  
Amplification and subsequent overexpression of oncogenes have been shown to be frequent in 
variety of neoplasias and is thought to play and important role in tumor development (Brison 
1993). Human cancers are able to amplify genes extrachromosomally, in the form of "double-
minutes" or "episomes", as well as intrachromosomally forming sometimes huge regions 
containing copies of contiguous genes. Early events of gene amplification were not available for 
study until model systems in cultured rodent cells were developed. Analysis of the induced 
amplicons in these systems revealed that the mechanism underlying the early amplification 
events is breakage-fusion-bridge cycles (Toledo et al. 1992).  
According to the model introduced by McClintock (Mc Clintock 1951) an initial break (or 
telomere dysfunction) of a chromatid bearing the selected gene might lead to the fusion of the 
uncapped sister chromatids after replication. The result would be dicentric chromosome forming 
an anaphase bridge between the centromers, which will break while moving to opposite poles of 
the mitotic spindle. If this break occurs centromeric to the selected gene, a duplication of the 
region between the breaks is gained. Several recurrent chromosomal fusion and breakage under 
the appropriate selection lead to interchromosomal amplification. The amplification resulted 
from BFB cycle, is easily recognizable by ladder-like structure which is the consequence of the 
inverted position of the copies. 
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Figure 1-1.  Schematic illustration of gene amplification via breakage-fusion-bridge cycles. Amplicons, yellow 
triangles; telomeres, orange (p-arm) or black (q-arm) circles; centromeres, orange rectangles. 
(A) Interphase; an initial break gives rise to an uncapped chromatid carrying the selected gene. (B) Metaphase; 
fusion of the 2uncapped sister chromatids results in a dicentric chromosome. (C) Anaphase; the dicentric 
chromosome forms a bridge between the opposite poles. A break of this chromosome leaves one daughter cell (D) 
with 3 copies of the selected gene, and only one copy in the other cell (E). Under a selection, recurrent cycles of 
BFB will occur, resulting in further accumulation of amplicon copies. (from Hellman et al. 2002) 
 
Molecular evidence demonstrated that breakage leading to oncogene amplification preferentially 
occurs within CFS regions. Since human CFSs encompass large genomic regions, different 
breakpoints within the fragile region are expected to occur during subsequent BFB (breakage-
fusion-bridge) cycles. Coquelle et al. (Coquelle et al. 1997) and Kuo et al. (Kuo et al. 1994) 
have provided evidence for breakage in CFSs which can drive amplification by BFB cycle in 
Chinese hamster ovary cell lines. It was shown that Met oncogene is amplified in human gastric 
cancer as a result of BFB cycles that initiate with FRA7G breakage (Hellman et al. 2002). A 
duplication of PIP gene in a breast carcinoma cell line has been associated to breakage in 
FRA7I. The same has been shown for other types of cancer like urothelial (Jin et al. 2007). In 
addition, an implication of FRA5C in amplification of SMAD5 was shown, not only in 
hepatocellular cell lines, but also in primary tumors (Zimonjic et al. 2003). This would be an 
evidence for the in vivo significance of CFSs for genome instability in cancers.  
It has been proposed that ex vivo induction of CFSs triggers and drives the amplification of drug 
resisted genes in rodent cells (Coquelle et al. 1997). Since many of the drugs used in cancer 
therapy are potential inducers of both fragile sites and gene amplification, they can lead to 
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chromosome rearrangements and further contribute to cancer development (Hellman et al. 
2002). 
 
 
1.2.2.3.       Mechanism of instability at common fragile sites 
 
1.2.2.3.1.      Unstable sequences and late replication at CFSs 
 
Sequence analysis of all cloned common fragile sites, unlike rare fragile sites, reveals no 
expanded di- or trinucleotide repeats or other sequences that can account for their fragility. The 
only feature they share with rare fragile sites is the relatively high amount of AT-rich sequence 
(Boldog et al. 1997; Mishmar et al. 1998; Ried et al. 2000; Shiraishi et al. 2001; Arlt et al. 
2002). Applying Flexstab, a computer program designed to measure local variation in the twist 
angel between the bases within a sequence (Mishmar et al. 1998), revealed regions of high 
flexibility (termed flexibility peaks) in CFSs. This structural characteristic of DNA could be 
important to understand the molecular mechanism of fragility at CFSs for two reasons: First, 
flexible DNA at the twist angle can act as a sink for the superhelical density generated ahead of 
the replication fork in its progress. Accumulating superhelical density can hinder efficient 
topoisomerase activity and decrease the processivity of the polymerase complex (Bacolla et al. 
1997; Gellibolian et al. 1997). Second, the twist angle was shown in vivo to affect the level of 
higher order-chromatin folding (Krajewski 1995; Krajewski and Ausio 1997). Flexibility 
analysis of common fragile sites FRA2G, FRA3B, FRAXB, FRA7E, FRA7H, FRA8C, and 
FRA16D, have shown that they contain a high number of flexibility peaks compared to non-
fragile regions (Mishmar et al. 1998; Ried et al. 2000; Arlt et al. 2002; Limongi et al. 2003; 
Zlotorynski et al. 2003; Ferber et al. 2004). These flexible sequences are composed of 
interrupted runs of AT-dinucleotides and may have the potential of forming secondary structures 
and, hence, may affect the replication of fragile sites. The first identification of a sequence 
element within a CFS which increases chromosome fragility was introduced by Zhang and 
colleagues (Zhang 2007). They suggested that long streches of AT dinucleotides within 
FRA16D cause increased chromosome breakage by forming secondary structures that stall 
replication fork progress.  
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 It has been shown that these flexible sequences have similarities to AT-rich minisatellite repeats 
that cause the fragility in rare fragile sites FRA16B and FRA10B (Zlotorynski et al. 2003). There 
are results from studying FRA8C which show a correlation between high flexibility peaks and 
HPV integration and translocation sites (Ferber et al. 2004).  
If these special sequences are necessary for the fragility of CFSs, then large deletions that 
remove these sites should cause the loss of fragility. Arlt et al. (Arlt et al. 2002) found that two 
tumor cell lines containing a 500-kb deletion in FRAXB completely eliminated fragility at this 
site. Moreover, stable transfecting of CFS sequences at ectopic sites exhibited instability, 
supporting a hypothesis that sequences at CFSs are inherently unstable (Ragland et al. 2008).  
On the other hand, an extensive study of FRA3B in cells with various deletions within the fragile 
site showed that deletion of large sequences in FRA3B did not affect fragility (Corbin et al. 
2002). Moreover, the regions of frequent breakpoints in cancer cells were mapped and no 
correlation between landmark (flexibility peaks, deletion and translocation breakpoints) and 
breakpoints in FRA3B were found (Corbin et al. 2002). These results suggest that loss of large 
regions within CFSs reduces, but not completely demolishes the fragility.  
Perhaps related to this sequence composition is the fact that common fragile sites are late 
replicating. It is long thought that CFSs, due to the sequences they contain, may have difficulties 
to replicate and that inhibition of replicative polymerases with aphidicolin further perturbs 
replication. It means late replication is possibly due to formation of secondary structures that 
inhibit replication fork progression, or other factors affecting replication dynamics at these 
regions. Le Beau et al. (Le Beau 1998) showed for the first time that sequences at FRA3B 
replicate very late and the addition of aphidicolin resulted in a further delay in replication with 
about 16.5% of FRA3B sites remaining unreplicated in G2.  
Since there are other regions in the genome that replicate late, this feature alone cannot underlie 
the fragility at CFSs. 
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1.2.2.3.2     Cell cycle checkpoints and repair pathways in common fragile site instability 
 
Little was known of cellular mechanism controlling CFS stability until recently when  
Casper et al. discovered that the Ataxia-telengiectasia and Rad3 Related (ATR) checkpoint 
kinase plays a major role in CFS maintenance (Casper et al. 2002). Cells evolve their cell cycle 
checkpoint to delay cell division in response to DNA damage to allow for their repair. ATR is a 
key player in the cellular response to stalled replication fork. It was demonstrated that in ATR-
deficient cells, even without the addition of replication inhibitors, CFSs were expressed 
(Gorgoulis et al. 2005). It was also found that cells from individuals with Seckel syndrome that 
have hypomorphic mutation in ATR are sensitive to aphidicolin and show increased stability at 
common fragile sites (Casper et al. 2004). ATR regulatory role was the first major pathway 
found to be associated to CFS stability and it was very important to link the cell cycle 
checkpoint function to fragile site stability. subsequent investigations focused further on 
defining these mechanisms and a number of targets or modifiers of ATR pathway are now 
known to affect fragile site maintenance, including BRCA1, the Fanconi anemia (FA) pathway, 
SMC1 and CHK1 (Arlt et al. 2004; Howlett et al. 2005; Musio et al. 2005; Durkin et al. 2006). 
Recently, it was published that in addition to ATR, ATM also plays a role in fragile site 
instability through a parallel pathway and the activation of ATM is independent of the activation 
of ATR, but they have synergic effects. Moreover, it was demonstrated that chk2 is activated by 
ATM in ATR deficient cells following addition of low doses of APH (Ozeri-Galai et al. 2008). 
All these data show that ATR, rather than ATM, has major (but not absolute) effect on CFS 
stability and the linkage with cell cycle checkpoint control. 
There is little data about how lesions at fragile sites are repaired. Homologous recombination 
repair (HRR) plays a major role in responding to DSBs and stalled replication forks during S 
and G2, when the sister chromatid is present. It has been reported that on average, 70% of all 
gaps and breaks at FRA3B after aphidicolin treatment had an SCE at that site (Glover and Stein 
1987). The presence of SCEs at fragile sites is an indication that some kind of repair has 
occurred at the site. Cells with mutation in RAD51 and other members of the HRR pathway 
have been reported to have reduced spontaneous and MMC-induced SCE formation, although 
the reduction is not severe and may even be species-specific (Fuller and Painter 1988; Tucker et 
al. 1991; Dronkert et al. 2000; Lambert and Lopez 2001; Takata et al. 2001; Stark et al. 2002; 
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Sasaki et al. 2004). These findings suggest that formation of DBSs at fragile sites is the result of 
replication perturbation and provides the first clues how lesions are repaired at CFSs. 
In addition to DNA damage, recent studies have suggested that alternative chromatin structures 
such as changes in histone modification, loss of histone chaperones, and alterations in 
chromosome condensation, can trigger repair processes and cell cycle checkpoints 
(Koundrioukoff et al. 2004). These findings combined with the involvement of proteins ATR, 
BRCA1, SMC, and the Fanconi Anaemia pathway in fragile site expression formulate a 
hypothesis on the involvement of chromatin structure in fragile site expression. Chromatin 
structure specific to fragile sites may (1) serve as a block to slow down or stall the progress of 
replication forks, (2) promote formation of unusual secondary structure by fragile DNA, or (3) 
cause failure of chromatin condensation (Wang 2006). 
Collecting data from a number of laboratories could support a working model for CFSs. It 
suggests that the AT-rich sequences at CFSs present difficulties during replication that are 
further exacerbated by APH and certain other forms of replication stress. When cells are treated 
with low dose APH, the polymerases slow or pause, likely leaving the helicase/topoI complex to 
continue unwinding DNA ahead of it, and resulting in long stretches of ssDNA that can activate 
the ATR-dependent DNA damage checkpoint. These ssDNA regions may form secondary 
structures, such as hairpins or cruciforms at the AT-repeats or AT-rich sequences associated 
with CFSs, which can further perturb replication as the polymerases encounter them. Although 
the majority of these perturbations are likely detected by the ATR-dependent DNA damage 
checkpoint and DNA repair machinery, some escape and present themselves as gaps and breaks 
on metaphase chromosomes, particularly at CFSs (Durkin and Glover 2007). 
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Figure 1-2.  A model for common fragile site instability. This model predicts that fragile sites are derived from 
long stretches of unreplicated ssDNA that are exposed when a replication fork is stalled or delayed, for example by 
treatment with APH. The ssDNA binding protein RPA (brown) coats the unreplicated ssDNA and recruits the DNA 
damage response checkpoint proteins, including ATR (red), which activate S-phase or G2/M checkpoints. Repair of 
these regions by proteins including RAD51 and DNA-PK restores replication fork progression. However, 
sometimes these regions escape checkpoint activation or are left unrepaired, resulting in an unreplicated region that 
can appear as a fragile site on metaphase chromosomes or lead to a DSB. (according to durkin glover 2007) 
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1.2.2.4   Evolutionary conservation of common fragile sites 
 
Fragile sites are quite stable in most normal somatic and germ cells. There is little evidence to 
link CFSs to constitutional chromosome rearrangements in humans. They also appear to be 
highly conserved during mammalian evolution. Orthologs of CFSs have been found in a number 
of other mammalian species, including other primates, cat, dog, pig, horse, cow, Indian mole rat, 
deer mouse and laboratory mouse (Soulie and De Grouchy 1981; Elder and Robinson 1989; 
Smeets and van de Klundert 1990; Stone et al. 1991; Stone et al. 1993; Yang and Long 1993; 
McAllister and Greenbaum 1997; Ruiz-Herrera et al. 2004). Of all these species, the most 
extensive work has been done in mouse. Three mouse fragile sites, Fral4a2, Fra8el, and Fra6cl 
have been cloned and found to be orthologs of human fragile sites FRA3B, FRA16D and 
FRA4A, respectively (Elder and Robinson 1989; Glover et al. 1998; Shiraishi et al. 2001; 
Krummel et al. 2002; Matsuyama et al. 2003; Rozier et al. 2004). The mouse fragile sites have 
some common features with human fragile sites, including AT-rich sequence and the presence 
of large genes. Furthermore, the high similarity of large intronic regions in mouse and human, 
suggests a functional conservation of these non-coding sequences. Such non-coding sequences 
may be conserved because they contain regulatory elements for associated gene function or 
perhaps due to the functional property of the CFS itself.  
This evolutionary conservation appears to extend from mammals to lower eukaryotes like yeast. 
It has been demonstrated that in Saccharomyces cerevisiae, temperature-sensitive mutants of the 
mec1 gene display double-strand breaks (DSBs) in specific genomic regions with slow-moving 
replication forks. Mec1 is an ortholog of ATR which has a role in the stability of CFSs in 
mammalian cells. 
The evolutionary conservation of CFSs is somehow puzzling. There are data demonstrating 
fragile sites to be significantly more frequently found at chromosomal regions that are 
repeatedly involved in rearrangements during evolution of the vertebrate lineage (Miro et al. 
1987; Ruiz-Herrera et al. 2005; Ruiz-Herrera et al. 2006). These findings suggest that fragile 
sites are prone to in vivo breakage during evolution, and may fulfill an important role in genome 
reorganization (Debacker and Kooy 2007). On the other hand, genomic regions that are prone to 
instability and rearrangements would be expected to be detrimental for the organism and 
therefore selected against during evolution. The fact that CFSs persist in the genome from yeast 
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to human, suggests they have a conserved function. CFS instability may simply be a side effect 
of a role of these sites in high-order chromosome structure or transcriptional regulation of 
associated genes. Or the fragility of these sites itself serves a purpose. Since they are late 
replicating, they may be among the last sites to replicate and signal to the cell that the 
replication is complete. Cell cycle checkpoint may specifically monitor these sites, blocking into 
mitosis until their replication is complete (Durkin and Glover 2007). 
 
 
1.3  Genome instability on the short arm of chromosome 9 
 
Short arm of chromosome 9 is the target of some of the most often described rearrangements in 
cancer. LOH and chromosomal deletions on the 9p have been reported as a frequent event in 
several cancers including clear cell carcinoma of the ovary (Kobayashi et al. 2009), meningioma 
(Bostrom et al. 2001; Perry et al. 2002), bladder cancer (Simoneau et al. 1996), pancreatic 
cancer (Sunamura et al. 2002), prostate cancer (Perinchery et al. 1999), nasopharyngeal 
carcinoma (Shao et al. 2002), lung cancer (Neville et al. 1995; Mao et al. 1996; Sato et al. 
2005), invasive and non-invasive pituitary adenomas (Farrell et al. 1997; Pack et al. 2005), oral 
cancer (Ishwad et al. 1996), acute lymphoblastic leukemia (Faienza et al. 1996), skin cancer 
(Carless and Griffiths 2008), thyroid cancer (Unger et al. 2008), osteosarcoma (Lim et al. 2005), 
breast cancer (An et al. 1999; Ellsworth et al. 2008) and neuroblastoma (Takita et al. 1997). As 
well as primary tumors, rearrangements occur also in tumor-derived cell lines. There are studies 
showing aberration on 9p in cervical cancer cell lines (Harris et al. 2003), renal cell carcinoma 
cell lines, glioma cell lines (Pomykala et al. 1994), Hodgkin lymphoma cell lines, 
neuroblastoma cell lines (Giordani et al. 2002) and breast cancer cell lines (Savelyeva et al. 
1999). Although most of these aberrations appear to be losses than gains, there are also data 
showing amplification of 9p region (Savelyeva et al. 1999; Lim et al. 2005). 
These findings suggest that the alteration of genetic material at 9p has an important role in the 
pathogenesis of different human cancers. It has been observed that LOH on 9p in neuroblastoma 
is more frequently detected in favorable NB stages and is statistically associated with a better 
clinical outcome in stage 4 patients (Mora et al. 2004).  
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The 9p21 segment including the p16/CDKN2A, p14/ARF and p15/CDKN2B loci has been 
defined as a common region for the deletions (Kamb et al. 1994; Nobori et al. 1994; Ohnishi et 
al. 1995; Tanaka et al. 1997; Drexler 1998; Hamada et al. 2000; Park et al. 2002). These genes 
are involved in the regulation of cell cycle and/or apoptosis (Sherr 2000). CDKN2A encodes  the 
16-kD p16, which is a tumor suppressor, interacts with the complex of cyclin D and the cell-
cycle-dependent kinase cdk4 or cdk6, and which inhibits the phosphorylation of the 
retinoblastoma protein (pRB) (Serrano et al. 1993).  
Chromosomal interstitial deletions and terminal deletions of a chromosome arm are two 
different critical events that may cause inactivation of tumor suppressors.  Interstitial deletions 
are supposed to be caused by DNA double strand breaks (DSBs) and subsequent illegitimate 
joining of DNA ends by homologous or non-homologous end joining repair. Since there is 
evidence confirming that DSBs can be formed at CFSs as a result of replication perturbation, 
one can envisage a role for CFSs in at least a number of frequently occurring deletions in cancer 
cells.  
To date, seven fragile sites have been recorded on chromosome 9. These include FRA9A to 
FRA9G. Among them, three of them are located on the short arm of chromosome 9. These are 
folate-sensitive FRA9A, and the two common fragile sites FRA9C and FRA9G.   
 
 
 1.3.1    FRA9G 
 
Previous studies in our laboratory (Sawinska et al. 2007) identified FRA9G as a novel 
aphidicolin inducible common fragile site, extending over a genomic region of 302 kb at 
chromosome band 9p22.2.  
In agreement with the known characteristics of other CFSs, FRA9G does not contain any 
expanded CGG-trinucleotide repeats or AT-rich minisatellite repeats and appears to be AT-rich 
(63.76%). Total amount of interspersed elements represet 58.9% of FRA9G sequence. This is 
composed mainly of LINE1 elements (35.66%), but it contains also LINE2 (3.44%), Alu 
(7.23%), MIR (1.2%), long terminal repeats (LTR) (8.34%) and DNA elements (3.03%). 
Compared to other CFSs, FRA9G has relatively high content of LINE1 element however it does 
not further help to undestand the nature of fragile site susceptibility to breakage. 
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Figure 1-3. Transcriptional and physical map of the FRA9G region. (a) Location of DNA markers relative to 
CNTLN gene (horizontal black lines). (b) Genomic structure of the CNTLN gene. Sizes for the six largest introns 
are indicated. (c) The BAC clones that correspond to the represented region. (Fig. from Sawinska et al) 
 
Similar to many other CFSs, FRA9G was found to be located within a single gene. According to 
Ensemble Database, FRA9G maps within CNTLN gene which spans 369 kb (Fig. 1-3). 
 
 
1.3.2.    FRA9C 
 
FRA9C is a BrdU inducible common fragile site which has been long listed in the Database at 
short arm of chromosome 9. Recently in our laboratory and as the first BrdU inducible CFS, the 
chromosomal region of FRA9C was precisely characterized. The region that FRA9C spans was 
narrowed down to 713.5 kb between the loci identified by RP11-30O14 (centromeric signal) and 
RP11-438B23 (telomeric signal) (Sawinska et al. Unpublished data). Alignment of the sequence 
of FRA9C to Ensemble Database revealed that it spans a G/R chromosome boundary, mapping 
to the distal part of the 9p21.2 R band and the proximal part of the G-band 9p21.1.  
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Figure 1-4. Transcriptional and physical map of the FRA9C region. (a) Location of DNA markers relative to 
LINGO2 gene (horizontal black lines). (b) Genomic structure of the LINGO2 gene. Sizes for the six largest introns 
are indicated. (c) The BAC clones that correspond to the represented region (Fig. from Sawinska et al) 
 
 
Little is known about the BrdU inducible common fragile sites. Most of the knowledge about 
CFSs have been gained from APH inducible CFSs. The sequence analysis of FRA9C, similar to 
APH inducible sites, showed AT-rich sequence (64%) and no content of expanded di- or tri-
nucleotide repeats. Total interspersed elements represent 39.2% of the total sequence of FRA9C, 
consisting of Alu (3.92%), MIR (3.52%), LINE1 (17.17%), LINE2 (3.46%) long terminal 
repeats (LTR) (6.94%) and DNA elements (3.12%). Comparison of the FRA9C sequence with 
both telomeric and centromeric non-fragile flanking sequences shows no significant difference 
in quantity of particular repeat elements between these regions. To explore DNA helix 
flexibility in the FRA9C sequence, the TwistFlex program was applied and the outcome 
revealed 8.5 Flex Peaks per 100 kb for FRA9C. According to Zlotorynski et al, this number is 
5.7 for APH inducible CFSs. Moreover, comparison of the FRA9C sequence with that of 
common fragile sites including FRA9G, FRA3B, FRA16D, FRA13A and FRA1E, shows a 
considerable variation in repeat sequences, in particular LINE1 elements (Sawinska et al. 
Unpublished data). This observation is in contrast to what has been proposed for FRA3B, in 
 20
 
Introduction 
 
 
 
which  LINE1 elements are considered to have a probable major role in the DNA instability at 
the fragile locus (Mimori et al. 1999).  
According to database, FRA9C is located within leucine rich repeat and Ig domain containing 2 
gene (LINGO2). LINGO2 is a relatively large gene of approximately 770 kb with a transcript 
size of 2.8 kb. It consists of seven exons ranging in size from 33 bp (exon 4) to 2.1 kb (exon 7), 
and big introns with the longest being 282 kb (Fig. 1-4). The genomic region of FRA9C extends 
for an approximately 620 kb of the LINGO2 gene.  
LINGO2 belongs to LINGO/LERN gene family, which similar to NLRR, FLRT and LRRTM gene 
families in mammals, encode for type I transmembrane proteins containing 10-12 extracellular 
rich leucin repeats and short intracellular tails (Carim-Todd et al. 2003; Lauren 2003; Haines 
2005). The LERN proteins are often expressed in nervous system (Carim-Todd et al. 2003; 
Lauren 2003) and have been associated with neuronal regeneration (Ishii et al. 1996; Robinson 
2004). It has also been suggested by some studies that these leucin rich repeat transmembrane 
proteins may function in the regulation of cell signaling (Fukamachi 2002; Ikeda et al. 2004; 
Haines et al. 2006).  
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1.4    Aims of this study 
 
- To estimate the extent of genomic rearrangements affecting short arm of chromosome 
9 in various tumor models. Based on a high resolution array CGH, the aim was to precisely 
characterize the overall genomic alterations on 9p, including deletion, amplifications and 
duplications and also to explore their frequency in different tumor types.  
 
- To define the impact of the fragility at FRA9G/CNTLN and FRA9C/LINGO2 on 
genetic alterations on 9p. As CFSs are supposed to exhibit breakages in the early stages of 
tumorigenesis, and also alterations in some CFS genes contribute to cancer development, 
one important aim of this study was to explore the frequency of FRA9G/CNTLN and 
FRA9C/LINGO2 rearrangemnets in different tumor models. 
 
- To determine novel candidate tumor-susceptibility genes on 9p. Looking for for 
candidate genes associated in tumor development has been a primary task for cancer 
research. Herein, applying a high-resolution array would help to detect the most frequent 
target regions for genetic alterations on 9p, which leads to identify the most affected genes 
in the region. 
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2.  Materials and Methods 
 
2.1 Materials 
 
2.1.1  Chemicals 
 
5-Azacytidine                                                                                            
β-Mercaptoethanol                                                                                    
1,4-dithiothreitol (DTT)                                                                            
4,6-diamidino-2-2phenolyndole (DAPI)          
Car
Roche
Amersh
Appli
Car
Car
Car
J.T. B
Fluk
Appli
Acetic acid  
Agarose 
Bovin Serum Albumin (BSA) 
Dextran Sulphate 
Diethylpyrocarbonate (DEPC) 
Ethanol 
Ethidium bromide 
Ethylendiaminetertaacetic acid (EDTA) 
Formamide 
Glycin 
Isopropanol 
Magnesium Chloride 
Methanol 
Phenol 
Phenol-Chloroform 
Potassium Chloride 
Sodium acetate 
Sodium chloride 
Sodium citrate 
Sodium hydrogen carbonate 
Tris-(hydroxymethyl)-aminomethane-NaOH 
Tris-(hydroxymethyl)-aminomethane-HCl 
23              
           
       
   
Sigma-Aldrich, Munich
Merck, Darmstadt
l Roth GmbH, Karlsruhe
Sigma-Aldrich, Munich
Merck, Darmstadt
Invitrogen, Karlsruhe
 Diagnostics, Mannheim
am Biosciences, Sweden
Sigma-Aldrich, Munich
Sigma-Aldrich, Munich
Sigma-Aldrich, Munich
AppliChem, Darmstadt
Merck, Darmstadt
Chem GmBh, Darmstadt
Merck, Darmstadt
Merck, Darmstadt
Sigma-Aldrich, Munich
l Roth GmbH, Karlsruhe
l Roth GmbH, Karlsruhe
Merck, Darmstadt
l Roth GmbH, Karlsruhe
aker, Deventer, Holland
a Chemie GmbH, Buchs
Merck, Darmstadt
Sigma-Aldrich, Munich
Chem GmBh, Darmstadt 
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Tween 20                                                                                              Merck-Schuchardt, Munich 
                       
2.1.2   Other Materials 
 
Cell culture dishes 
Cell culture flasks  
Over slips 
Cryotubes 
Microscope slides 
Micro test tubes (1.5 – 2.0 ml) 
Parafilm "M" 
Pasteur pipettes 
PCR tubes 
Pipette tips 
Polyethylene-tubes (15 ml, 50 ml) 
Optical 96-well reaction plates, MicroAmp  
Rubber cement, Figogum 
Scalpels 
 
2.1.3   Laboratory Equipments 
 
ABI PRISM 7000, sequence detection system  
Apparutus for gel electrophoresis 
Baeuerle BS 785 Automatic Timer 
Biometra, TRIO thermoblock 
Counting cell chamber 
Freezer -20°C 
Freezer -80°C 
Heat block 
Hot cabinet, 37°C 
Hybridization System 4 
Incubators 
24Greiner Labortechnik, Frickenhausen
TPP, Trasadingen Schweiz
Menzel, Braunschweig
Nalgene Nunc, Wiesbaden
Menzel, Braunschweig
Eppendorf, Hamburg
American Natinal Can, Chicago
Brand, Wertheim
Abgene, Surrey, UK
Greiner Labortechnik, Frickenhausen
Labortechnik, Frickenhausen
Applied Biosystems, Weiterstadt
Marabuwerke, Tamm
PFM, KölnGIBApplied Biosystem, Weiterstadt
CO/BRL, Eggenstein, Darmstadt
St. Georgen/Schwarzwald
Biometra, Göttingen
Migge, Heildelberg
Liebherr, Germany
New Brunswick Scientific, USA
Eppendorf, Hamburg
Heraeus, Osterode
NimbleGen  Inc, USA
W. Schreck, Hofheim 
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UniEquip, Martinsried
Heidolph-Elektro, Kehlheim
Leica Microsystems, Wetzler
NimbleGen, USA
Thermo Fischer Scientific, USA
Heraeus, Osterode
Applied Biosystems, Darmstadt
Amersham-Pharmacia, Freiburg
Integra Biosciences GmbH, Fernwald
BiotechFischer, Reiskirchen
Janke and Kunkel, Staufen
Biorad, Munich
Eppendorf AG, Hamburg
Bachofer, Reutlingen
Heidolph-Elektro, Kehlheim
Köttermann, Uetze-Hänisgen 
Lamin airflow cabinet Uniflow 1800 
Magnetic stirrers 
Microscope Leica DMRA 2 
MS 2000 Microarray Scanner 
Nanodrop, Spectrophotometer ND-1000 
Oven 
PCR-Thermoblock GeneAmp 9700 
Photometer, Ultroscope 3000 
Pipetboy 
Power supply unit Pherostab 500 
Shaker IKA KS250 
System for gel documentation (Geldoc) 
Thermomixer compact 
Vaccum-Concentrator 
Vortex-Shake 
Waterbath 
 
Centrifuges 
Heraeus, Osterode
Heraeus, Osterode
Eppendorf. Hamburg
Beckman Inst, Munich
Beckman Inst, Munich
Beckman Inst, Munich
Beckman Inst, Munich
Beckman Inst, Munich
Beckman Inst, Munich
Biofuge fresco 
Biofuge pico 
Eppendorf Centrifuge 5417R 
J-6 M/E Centrifuge 
J2-21 M/E Centrifuge 
Avanti-J-25I 
 
Rotors 
JS 4.2 
JA 10 
JA 20 
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2.1.4   Antibiotics 
Ampicilin 
Penicillin, Streptomycin 
Kanamycin 
 
2.1.5   Enzymes 
DNA polymerase I E.coli 
DNase I / RNase free 
Klenow fragment 
Pepsin 
Reverse transcriptase (Superscript III) 
RNase A 
Taq DNA polymerase 
Trypsin 
 
2.1.6  Fluorescent dyes 
Cy3 
Cy3.5 
Cy5 
Cy5.5 
DEAC 
FITC 
 
2.1.7   Kits, Medida and solutions 
First Choice Total RNA: Human Normal Tissues 
Platinum SYBR Green qPCR SuperMix-UDG 
AppliChem, Darmstadt
Serva, Heidelberg
Serva, Heidelberg
MBI-Fermentas, St.Leon-Rot
Roche Diagnostics, Mannheim
MBI-Fermentas, St.Leon-Rot
Sigma-Aldrich, Munich
Invitrogen, Karlsruhe
Roche Diagnostics, Mannheim
Promega, Mannheim
Amersham Biosciences Europe GmbH, Germany
Amersham Biosciences Europe GmbH, Germany
Amersham Biosciences Europe GmbH, Germany
Amersham Biosciences Europe GmbH, Germany
Molecular probes Inc, Eugene, USA
Molecular probes Inc, Eugene, USA
Ambion, USA
Invitrogen, Karlsruhe
Qiagen, Hilden
Qiagen, Hilden
Qiagen, Hilden
Invitrogen, Karlsruhe
Life Technologies, Munich
Qiagen Plasimd Maxi Kit 
QIAquick Gel Extraction Kit 
QIAquick PCR Purification Kit 
First-Strand cDNA synthesis kit for RT-PCR 
Fetal Bovin Serum (FBS) 
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M
M
Ro
RPMI 1640, cell culture medium 
TRIZOL TM Reagent 
 
2.1.8   Nucleic Acids 
1 kb DNA-Ladder, Gene Ruler 
100 bp DNA-Ladder, Gene Ruler 
Cot-1 DNA 
dNTPs 
OLIGO(dT)23 Anchored 
Salmon sperm DNA 
 
2.1.9   Buffers and solutions 
 
1x PBS 
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4, pH 7.4 
 
20x SSC 
3 M  NaCl 
0.3 M NaCitrate, pH 7.0 
 
TBE-buffer 
50 mM Tris 
50 mM boric acid 
1 mM EDTA 
 
TE 
10 mM Tris.Cl 7.4 or 7.5 or 8.0 
1 mM EDTA, pH 8.0 
 
 
27Life Technologies, Munich
Invitrogen, Karlsruhe
BI Fermentas, St.Leon-Rot
BI Fermentas, St.Leon-Rot
Life Technologies, Munich
Sigma-Aldrich, Munich
Sigma-Aldrich, Munich
che-Diagnostics, Mannheim 
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Freezing medium  
20 % (v/v) DMSO 
80 % (v/v) FCS 
prepared freshly before use 
 
 
DNA fragments separation in gel agarose 
 
Agarose gel 
1% Agarose 
1x TBE-buffer 
DNA-loading buffer 
15% (w/v) Ficol Type 400 
0.25% (w/v) Xylencyanol 
0.25% (w/v) Bromophenol blue 
 
Ethidium bromide  
Stock: 10 mg/ml in H2O 
For gel: 5 ml stock/100 ml 
 
Cell fixation and fluorescence in situ hybridization 
 
Blocking solution 
4x SSC 
3% BSA 
 
DAPI 
Stock: 0.25 mg/ml H2O 
 
Denaturation solution 
70% deionized formamide 
2x SSC 
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Detecrion buffer 
4x SSC 
1% BSA 
0.1% Tween 
 
Fixative solution  
Methanol 
Acetic acid 
In proportion 3:1 
 
Hybridization solution 
4x SSC 
20% dextran sulphate 
 
Hypotonic solution 
0.55% KCl 
1% NaCitrate 
In proportion 
 
10x nick translation buffer 
0.5 M Tris-HCl. pH 8.0 
50 mM MgCl2 
0.5 mg/ml BSA 
 
PBS/MgCl2-solution 
1x PBS 
0.25 M MgCl2 
 
PBS/MgCl2/formaldehyde-solution 
1x PBS 
0.25 M MgCl2 
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2.7% formaldehyd 
 
Pre-treatment solution 
99 ml H2O 
1 ml HCl 
50 µl pepsin 
 
RNase-solution 
200 µg/ml 
2x SSC  
 
 
2.1.10  Oligonucleotides 
Below are the custom oligonucleotides were synthesized and purified by HPLC by Sigma: 
 
CNTLN-forward primer 
5' AAGGAACCACCTGTGAAACG 3' 
CNTLN-reverse primer 
5' GATTTCAGCCGATTTTCCAA 3' 
LINGO2-forward primer 
5' TGAGCTGCCTGCACTTCTAA 3' 
LINGO2-reverse primer 
5' TGGTGGATCCCATGAAGATT 3' 
GAPDH-forward primer 
5' ACCACAGTCCATGCCATCAC 3' 
GAPDH-reverse primer 
5' TCCACCACCCTGTTGCTGTA 3' 
CNTLN (real-time)-forward primer 
5' CCGATCAACGATTTCAGACA 3' 
CNTLN (real-time)-reverse primer 
5' GGGAATTTTCTTCTGCCAAA 3' 
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GAPD (real-time)-forward primer 
5' TGGACCTGACCTGCCGTCTA 3' 
GAPD (real-time)-reverse primer 
5' CCCTGTTGCTGTAGCCAAATTC  
 
2.1.11   Plasmids 
BACs 
  
2.1.12   Software 
GenePix 
Leica CW4000 
NimbleScan, version 2.4.27 
SignalMap, version 1.9.0.03  
Microsoft Excel 2000  
Microsoft Photoshop 7.0 
 
2.1.13   Online Databases and Programs 
Primer3, Web Interface Whitehead  
Institute for Biomedical Research 
National Center for Biotechnology  
Information (NCBI) 
Ensembl database 
UCSC Genome Browser 
Wellcome Trust Sanger institute 
COSMIC project 
RepeatMasker program 
Perfect Microsatellite Repeat Finder  
http://www.sa
http://sgdp.iop.kcl.ac
ht
Deutsches Ressourczentrum für Genomforschung  (RZPD), Berlin
Agilent, USA
Leica Microsystems, San Jose, USA
Roche NimbleGen, USA
Roche NimbleGen, USA
Microsoft Corp.
Adobe Systems Inc.
TwistFlex program 
 
 
 
 
31http://frodo.wi.mit.edu/primer3
http://www.ncbi.nlm.nih.gov
http://www.ensembl.org
http://genome.ucsc.edu
nger.ac.uk/genetics/CGP/cosmic
http://www.repeatmasker.org
.uk/nikammar/repeatfinder.html
tp://margalit.huji.ac.il/TwistFlex 
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2.1.14   Human tumor cell lines  
 
Cell line                                            Reference                   
   
LAN6 
 
Kelly 
                                                             
NGP 
 
CHP-134 
                          
SK-N-FI 
                                                      
SK-N-BE(2)C 
                                                      
HDN-33 
     
Vi-856 
 
SH-EP 
 
H-4 
 
U-87 MG 
 
U-373 MG 
 
U-138MG 
 
A 172 
 
Hs-683 
 
HDC-54 
 
HDC-57 
 
HDC-73 
 
HDC-75 
 
HDC-87 
 
COLO-824 
BT-20 
 
BT-474 
 
MX-1 
 
                                                          
        
                
Savelyeva et al, 1995 
 
Thiele, 1998 
 
Brodeur et al, 1977 
 
Schlesinger et al, 1976 
 
Thiele, 1998 
 
Thiele, 1998 
 
DKFZ 
 
Savelyeva et al, 1995 
 
Thiele, 1998 
 
Arnstein et al, 1974 
 
Ponten J et al, 1968 
 
Ponten J et al, 1968 
 
Ponten J et al, 1968 
 
Giard DJ et al, 1973 
 
Owens RB et al, 1976 
 
DKFZ, tumorgenetics department 
 
DKFZ, tumorgenetics department 
 
DKFZ, tumorgenetics department 
 
DKFZ, tumorgenetics department 
 
DKFZ, tumorgenetics department 
 
Savelyeva et al, 1999  
Lasfargues et al, 1958 
 
Lasfargues et al,  1978 
 
Ovejera AA et al, 1978 
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T-47D 
 
SK-BR-3 
 
MDA-MB-436 
 
MFM-223 
 
MCF-7                                                                                                   
Keydar I et al, 1979 
 
Fogh J et al, 1977 
 
Cailleau R et al, 1978 
 
Hackenberg et al, 1991 
 
Soule HD et al, 1973
 
 
 
2.1.15   Lymphoblastoid cell lines from healthy individuals 
 
Cell line                                            Description                   
   
UM 
 
UV 
 
327M 
 
327F 
                                                                                                                      
303 
 
327 
 
                                                                                          
Female, EBV-transformed- lymphocytes, wild type 
 
Male, EBV-transformed- lymphocytes, wild type 
 
Female, EBV-transformed- lymphocytes, wild type 
 
Male, EBV-transformed- lymphocytes, wild type 
 
Male, EBV-transformed- lymphocytes, wild type 
 
Female, EBV-transformed- lymphocytes, wild type 
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2.2   Methods 
 
2.2.1   Array CGH 
 
Test (human tumor cell lines) and reference (lumphoblastoid cell lines from healthy individuals) 
DNA Samples were applied in array-based comparative genomic hybridization experiments. 
Purified, unamplified, and unfragmented genomic DNA (gDNA) is required optimal sample 
labeling and hybridization. The whole procedure was done following manufacturer's protocol 
(Roche NimbleGen CGH array). 
 
Sample preparation 
Both test and reference DNA were sonicated to produce a smear of DNA from ~500 bp to 
~2000 bp. On 1% agarose gel, genomic DNA should appear as a single prominent band greater 
than 12 kb. Degradation and/or RNA contamination appear as more than one band or as a smear, 
which could affect the labeling procedure. Such samples are not suitable for aCGH analysis. 
 
Sample labeling  
Cy3-Random and Cy5-Random Nanomers are diluted as below: 
 
    Random Primer Buffer 998.25 µl 
    β-Mercaptoethanol 1.75  µl 
    To the final volume of 1 ml 
Diluted primers are aliquoted and stored at -20°C. 
 
Then 1 µg of test and reference samples were mixed with 40 µl of diluted Cy3 and Cy5, 
respectively. Then the samples were denaturated at 98°C for 10 min and quick chilled for 2 min. 
The following dNTP/Klenow Master Mix was prepared and added per sample: 
 
    10 mM dNTP Mix 10 µl 
    Nuclease-free water 8 µl 
    Klenow Fragment (3->5 exo-) 2 µl    
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The next step was to mix the 20 µl of dNTP/Klenow Master Mix with 80 µl of dilution of DNA 
samples and the Nanomers. They were then mixed well by pipetting and incubated for 2 h at 
37°C.  
The reaction is stopped by adding 10 µl of 0.5 M EDTA solution. After adding 11.5 µl of 5M 
NaCl and 110 µl of isopropanol, the samples were vortexed well and incubated for 10 min at 
RT. By removing the supernatant from centrifugation at 12000 x g for 10 min, pink (Cy3) and 
blue (Cy5) pellets were remained. The pellets were rinsed with 500 µl 80% ice-cold ethanol by 
2 min centrifugation. The pellets at this stage could be stored dried at -20°C. Otherwise, the 
samples were diluted in 25 µl nuclease-free water, vortexed well and the concentration of each 
sample was caculated by Nanodrop. At this step also the pellets could be stored protected from 
light at -20°C. 
 
Hybridization and washing 
Using components from NimbleGen Hybridization Kit, the following hybridization solution 
master mix was prepared for each slide (3x720K array): 
     
    2x Hybridization Buffer  35 µl 
    Hybridization component A 14 µl 
    Alignment Oligo   3.6 µl  
 
From the master mix, 14.4 µl was mixed with 5.6 µl of the labeled sample, incubated at 95°C 
for 5 min and then loaded to each slide. The mixers were loaded on the slides and sealed 
perfectly according to manufacturer's manual. Finally, the slides were placed in the 
hybridization system and incubated at 42°C for 40-72h. 
All the further washing steps and scanning the slides were performed as described in 
NimbleGen protocol. 
The results were analyzed using SignalMap and NimbleScan softwares provided by NimbleGen. 
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2.2.2   Cytogenetic techniques 
 
Preparation of metaphases 
In order to excite cells division and also to increase the amount of the cells in metaphase, fresh 
medium was added to cells one day prior to metaphases preparation. For harvesting, cells were 
centrifuged at 800 rpm for 6 min at room temperature, following the cells pellet was 
resuspended in 10-12 ml (depending on the pellet size) of fresh hypotonic solution and 
incubated for 15-25 min at RT. Longer hypotonic incubation (45-60 minutes) or the use of more 
hypotonic buffer resulted in longer, thicker, stickier chromosomes, very difficult to spread, 
yielding poor banding but still good FISH signals. Too short hypotonic treatment leaves cell 
membranes and cell/nuclear debris around the chromosomes, which do not spread properly and 
have poor banding and hybridization quality. 
After hypotonic treatment and before centrifugation (800 rpm, 5 min, room temperature), 1ml of 
fixative solution (3:1 parts absolute methanol/glacial acetic acid) was added. For fixation, the 
cell pellet was resuspended in 5 ml of fixative solution and incubated for 15 min at RT. The 
fixative solution preserves the cells in their “swollen” state after hypotonic treatment, removes 
lipids and dentures proteins thus making the cell membrane very fragile, which helps 
chromosome spreading. After incubation, the cell suspension was again centrifuged at 800 rpm 
for 5 min, the supernatant removed and pellet cells were washed in fixative solution. This 
procedure was repeated three times. After the last centrifugation step, cells pellet was 
supernatant in fresh fixative and stored for years at -20°C. Prior to slide preparation, the 
supernatant was removed and replenished with fresh fixative when stored longer than 5-6 days 
in refrigerator or more than two weeks in a freezer. 
 
                     Hypotonic solution              absolute methanol, glacial acetic acid, in proportion 3:1 
                         Fixative solution                  0.55 % KCL 1 % NaCitrate, in proportion 1:1 
 
Slides preparation  
Glass slides were washed and rinsed in double distilled water. With an automatic pipette,  
20-30 µl of cell suspension was evenly distributed on several locations on the slide and spread 
the liquid by gently moving the pipette tip parallel to the surface. As the fixative gradually 
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evaporated, the surface of the slide became “grainy” (cells visible). Afterwards, the slide was 
faced down into the steam of the hot water bath (~60°C) for 2-4 seconds and then air-dried. 
An alternative method consisted in dropping 2-3 drops of cells suspension using Pasteur pipette 
on the preheated for several seconds (water bath, ~60°C) slide from 10-15 cm distance. Cells 
were evenly distributed on the surface. Excess liquid was drained on a paper towel and the slide 
was air-dried. The degree of spreading was adjusted using the different temperature of water 
bath, with higher temperatures increasing chromosomes spreading. 
The quality of the slides was verified with the help of light-optical microscope. 
 
Aging of slides-dry heat 
Prior to fluorescence in situ hybridization, slides were aged either by incubating 2-3 days at RT, 
or at 37°C for 2 days, or overnight at 65°C. However, aging has to be gentle enough to allow 
optimal access of the labeled DNA probe to the target chromosomal DNA. Very fresh slides, if 
not aged, might either lose most of the nuclei/chromosomes during denaturing or the shape of 
the chromosomes will become much distorted (“puffy” chromosomes). Too long aging can 
sharply decrease the efficiency of hybridization. 
 
Fluorescence in situ hybridization 
In fluorescence in situ hybridization (FISH), a DNA probe is labeled with a fluorescent dye or a 
hapten (usually in the form of fluor-dUTP or hapten-dUTP, which is incorporated into the DNA 
using enzymatic reactions, such as nick translation or PCR). The labeled DNA is purified, 
concentrated, resuspended in hybridization buffer (containing formamide) and is hybridized 
onto chromosomes and nuclei on slides (cytogenetic preparations). After overnight 
hybridization, the slides are rinsed in washing solutions and, if needed, one or several layers of 
fluorescent-labeled antibodies are added to detect hapten-labeled DNA. The slides are mounted 
with antifade solution and are visualized at the fluorescent microscope, using appropriate filters. 
 
Chemical coupling – synthesis of labeled nucleotides 
As previously described (Henegariu et al. 2000), labeled nucleotides were synthesized by 
chemically coupling allylamine-dUTP to succinimidyl-ester derivatives of fluorescent dyes: 
DEAC (diethyl aminomethyl coumarin), FITC (fluorescein isothiocyanate), Cy3, Cy3.5, Cy5, 
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Cy5.5. The latter require fluorescently-labeled antibodies or specific proteins for 
visualization/detection. The reactive nucleotide (allylamine-dUTP), are all available 
commercially as dry powders, in 5-10-25 mg aliquots. Most of the days can be dissolved in 
DMSO, but some, for instance CB and 488 (the acetylazide derivative of Alexa 488, 
respectively) are soluble in water. Chemical coupling reactions were carried out at 2:1 molar 
concentration (dye: dUTP) in 80-100 mM bicarbonate buffer, adding the allylamine-dUTP (20 
mM stock solution, in 0.2 M bicarbonate buffer) first, and the reactive dye last. 
 
                                     Aminoallyl-dUTP              1 mg AA-dUTP/100 µl 0.2 M bicarbonate buffer 
                                     Bicarbonate buffer            0.2 M NaHCO3 (pH 8.3) 
                                     Glycine                               2 M glycine, pH 8 
                                     Tris-HCl                            1 M Tris-HCl, pH 7.75 
 
 
After 3-4 hours of incubation at RT, glycine was added to every reaction in order to stop 
reaction, then Tris-HCl to stabilize the nucleotides and H2O. Nucleotides could be used 
immediately or stored at -20°C. 
 
Nick translation – enzymatic DNA labeling 
The labeling of FISH probes was carried out by nick translation with fluorescence dyes-dUTP 
such as Cy3-dUTP, Cy3.5-dUTP, FITC-dUTP, DEAC-dUTP, Cy5-dUTP and Cy5.5-dUTP. 
A standard nick translation reaction included: 
 
                               2-3 µg                        DNA 
                                     10 µl                          0.1 M β-Mercaptoethanol  
                                     10 µl                          1× nick translation buffer  
                                     10 µl                          10× dNTP-mix 
                                     3 µl                            DNase I (0.03 U/µl) 
                                     2µl                             E.coli DNA-polymerase I (10 U/µL) 
                                     H2Odd                       to 100 µl final volume 
 
The reaction was mixed on ice and subsequently incubated at 15°C for 45-55 min. During 
incubation DNase I in the presence of Mg++ becomes a single stranded endonuclease and 
creates random nicks in the two strands of any DNA molecule. E.coli polymerase I which 
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through its 5’-3’ exonuclease activity removes nucleotides “in front” of itself, while the 5’-3’ 
polymerase activity adds nucleotides to all the available 3’ ends created by the DNase. This 
exonuclease/polymerase activity, moves (or “translates”) any single stranded nick in the 5’-3’ 
direction. When nicks on opposite strands meet, the DNA molecule breaks. 
The enzymatic activity was stopped by incubation of vials on ice. The size of labeled DNA 
fragments used for hybridization was verified by electrophoresis and 8 µl of every sample was 
run on 1 % agarose gel. Their size needs to be between 200-500 bp long, otherwise, a relatively 
high backgrounds starts to become visible on the slides and the hybridization signals become 
more punctuate. 
 
          10 × nick translation buffer                    0.5 M Tris-HCl (pH 8.0), 50 mM MgCl2, 0.5 mg/ml BSA 
         10 × dNTP-mix                                        50 µl 1 mM dNTP (dATP, dCTP, dGTP), 15 µl 1 mM dTTP,  
                                                                             35µl 1   mM labeled dUTP 
 
Preparation of DNA probes for in situ hybridization  
After nick translation, the labeled DNA needs to be processed and purified before it is used as a 
probe in FISH. 
 
Chromosomal in situ suppression (CISS) hybridization 
Since the interspersed elements are present in a probe, application of the standard procedure 
results in hybridization signals distributed over the whole chromosome complement due to the 
ubiquitous presence of repetitive sequences throughout the genome. These elements can be 
suppressed in a given probe, while a highly specific signal is produced by the target site specific 
sequences. The method has been called chromosomal in situ suppression (CISS) hybridization. 
The labeled probe fragments are denaturated together with an excess of unlabeled competitor 
DNA (Cot-1 DNA). Thereafter, pre-annealing is allowed for a given period of time. During this 
time, repetitive elements of the probe will hybridize rapidly with abundant chromosome specific 
sequences remain single-stranded. Accordingly, the resulting double-stranded repetitive 
elements in the pre-annealed probe can no longer hybridized to their chromosomal DNA targets. 
Remaining single-stranded repetitive sequences will hybridized to chromosomal repetitive 
targets during the subsequent in situ hybridization. 
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 For each nick translation, DNA probe was mixed Cot-1 fraction of human genomic DNA  
(10 µg Cot-1 DNA pro 100 µl of nick translation volume) and 4 µl of salmon sperm (20 µg per 
100 µl of nick translation). The mix was precipitated with 2.5 volume of absolute ethanol, 
incubated for 30 min at -80°C, and afterwards centrifuged at 13000 rpm for 30 min, at 4°C. The 
dried pellet was dissolved at 65°C in 15 µl per slide of deionized formamide and after addition 
of 15 µl of hybridization buffer, well mixed and denaturated for 10 min at 90°C. 
Pre-annealing was performed for 30-60 min at 37 °C. After incubation, the probe was 
completely prepared for hybridization with the pre-treated metaphase chromosomes. 
 
             Deionized formamide                        deionized with 100 g Mixed Bed Resin/1 l formamide 
                Hybridization buffer                         4× SSC, 20 % dextran sulphate 
 
Pretreatment and in situ hybridization of metaphase chromosomes 
Before hybridization of DNA probe to the metaphase preparation, the slides were treated with 
RNase and pepsin. For RNase treatment, which serves to remove endogenous RNA and may 
improve the signal to noise ration in hybridization to DNA targets, 300 µl of RNase-solution 
was put onto microscope slides, covered with cover slips and incubated for 1 h at 37°C. 
Afterwards, the slides were rinsed three times with 2× SSC for 5 min each, at 42°C. After this 
incubation, the digestion of proteins that surround the target nucleic acid was performed with  
50 µg/ml pepsin in 0.01 M HCl-solution at 42°C for 10 min to increase accessibility. Following, 
the slides were washed twice for 5min each, at 42°C, at first in 1 × PBS and then in PBS/MgCl2-
solution. The next fixation was performed in 1%iger formaldehyde-solution (in PBS/MgCl2-
solution) for 10 min at room temperature and after this the slides were washed in 1×PBS for 5 
min at 42°C. Finally the slides were dehydrated in ethanol series (70 %, 90 %, 100 %), each for 
3 min at RT and air-dried. Immediately before hybridization with DNA probes, chromosomes 
were denaturated in 70 % formamide (FA)/2 × SSC in Coplin jar) at 70-74 °C, followed by 
rising, 3 min each in 70 %, 90 % and 100 % ice-cold ethanol at room temperature. After air-
drying, previously prepared probe mixture was spotted onto thee cell sample and glass cover 
slips were carefully applied. Drying up of probe was prevented through sealing the edges of 
slides with rubber cement (Fixogum) during overnight hybridization at  
37 °C in a humidified chamber. 
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2.2.3  Nucleic acid manipulations 
 
2.2.3.1   Total RNA extraction 
Total cellular RNA from cell lines was isolated using TRIZOL. This reagent is a monophasic 
solution of phenol and guanidine isothiocyanate, which is able to effectively dissolve cellular 
components ensuring the integrity of the RNA molecules through the isolation procedure. After 
addition of chloroform, the TRIZOL containing solution separates onto an aqueous RNA 
containing phase and an organic phase. RNA can be easily recovered from aqueous phase by 
precipitation with isopropanol. 
Cell culture medium was discarded from the culture dishes and then TRIZOL was added 
directly to cells. Lyzed cells were transferred into the RNase-free polypropylene tubes and 
incubated for 5 min at RT. To separate the aqueous phase, 0.2 ml of chloroform per 1 ml 
TRIZOL was added to each tube. Samples were mixed by vortexing for 1 min and then 
centrifuged at 10,000x g for 10 min at 4°C. After centrifugation, the upper colorless aqueous 
phase was collected and RNA was precipitated with equal volume of isopropanol alcohol. The 
RNA pellet, obtained after centrifugation for 15 min at 12,000x g, was then washed once with 
75% ethanol and air0dried for 5 min. RNA was dissolved in RNase-free water and the amount 
of RNA in each sample was estimated on a spectrophotometer, reading the absorbance at 260 
nm.  
 
2.2.3.2   Reverse transcription of total RNA and RT-PCR 
To generate the first strand cDNA, total RNA was reversely transcribed using the SuperScript™ 
III Reverse Transcriptase from Invitrogen according to the manufacturer's instructions. The 
First- Strand cDNA synthesis reaction was conducted as below: 
RNA and oligo(dT)12-18 primers were denaturated at 65°C for 5 min and placed on ice and                   
mixed with dNTPs: 
                                                    1µl Oligo(dT) primer (50µM) 
                                                     1 µg RNA 
                                                     10 mM dNTPs (10mM) 
                                                      H2O up to final volume of 13 µl 
 
To the chilled RNA/oligo mixture, the following master reaction mix was added: 
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                                    4 µl 5x First Strand Buffer 
     1 µl 0.1 M DTT 
     1 µl SuperScript RT (200 units/µl) 
     
The reaction mixture was mixed well and incubated for 60 min at 50°C. Then the 
reaction was terminated at 85°C for 5 min. The final samples could be diluted and stores 
at -80°C. 
 
To amplify CNTLN and LINGO2 cDNA, the first strand cDNA was used for PCR amplification 
with the specific primers described before. The primers were designed with the Primer3 
software and were ordered from Sigma. 
 PCR reactions were set up as below: 
 
     2 µl RT reaction 
     5 µl 10x PCR Buffer 
     0.5 µl dNTPs 
     1 µl primer forward 
     1 µl primer reverse 
     0.5 µl Taq DNA polymerase (5 U/µl) 
     H2O to the final volume of 50 µl 
 
And cycling conditions were:  
    94°C 2 min 
 35 cycles  94°C 30 sec 
    55°C 45 sec 
    72°C 60 sec 
    72°C 7 min 
 
The fragment of cDNA of the housekeeping gene GAPDH, amplified with the primers described 
in 2.1.10, was used for normalization of the results. 
    
2.2.3.3   Quantitative RT-PCR  
For quantifying the expression of CNTLN in normal tissues, the total RNA of normal human 
tissues (Ambion) were subjected to reverse transcription and then the obtained cDNA was 
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analyzed by real-time RT-PCR. The analysis was performed using SYBR green assay 
(Invitrogen) according to manufacturer's protocol. The primers were designed with the Primer3 
software in a way that they cross exon-intron boundaries. They were the ordered from Sigma. 
The PCR reaction for the First-Strand cDNA was as below: 
 
    13 µl   Platinum SYBR Greenq PCR SuperMix UDG (2x) 
    1.25 µl   forward primer (6pmol/µl) 
    1.25 µl   reverse primer (6pmol/µl) 
    2.5 µl  template cDNA 
    7  µl  H2O  
 
The reaction was carried out in ABI PRISM 7900 detection system (Applied Biosystems) using 
the following conditions: 
  40 cycles 95°C 15 min 
         94°C 15 sec 
    55°C 30 sec 
       
The results obtained from CNTLN qPCR were normalized by GAPD housekeeping gene qPCR 
results. 
 
2.2.3.4   Genomic DNA extraction 
To isolate the genomic DNA, cells from 150 mm plates were trypsinized and collected in 15 ml 
falcon tubes. They were then washed using 10 ml PBS and centifugating at 800 rpm for 5 min. 
The pellet was then resuspended in 2 ml of lysis buffer and incubated for 1h at 56°C. 
 
    Lysis Buffer 8.3 g   NH4Cl 
      1 g      KH2CO3 
      0.37     EDTA 
      H2O up to 1 L 
 
Five ml of phenol/chloroform was added to the lyzed solution, vortexed and centrifuged at 3000 
rpm for 5 min. The aquouse layer was then collected and transferred to a new 15 ml falcon tube 
and again 5 ml phenol/chloroform was added, followed by centrifugation. Afterwards, the 
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aqueous phase was transferred to a 50 ml falcon tube containing 30 ml of Ethanol 100% and 3ml 
NH4AC (3 M). It was mixed gently until DNA was precipitated.  
Genomic DNA was then spooled onto a glass rod and washed by dipping the rod into 1 ml of 
70% ethanol. In the end the DNA was detached from the rod and dissolved completely in water. 
 
2.2.4   Culture of cells 
All cells were grown at 37°C in a cell incubator in a 5% carbon dioxide/100% humidity 
atmosphere. All cell culture media were supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin and 10% fetal bovine serum. Most adherent cells were detached from the surface 
of the cell culture flasks with the help of a trypsin / EDTA solution. Before the detachment the 
growth medium was removed and the cells were washed by the careful addition and subsequent 
removal of 10–20 ml PBS. Then 40 µl trypsin/EDTA solution per square centimeter surface was 
added and the cells were kept for 5–10 minutes at 37°C in a cell incubator. When the cells were 
detached they were washed in 10–20 ml growth medium to inactivate the trypsin/EDTA and 
used for further experiments. 
 
2.2.5   Freezing and thawing of cells 
In order to freeze mammalian cells, 1*106 to 1*107 cells were suspended in 500 µl of the 
respective growth medium. To the cell suspension 500 µl freezing medium was added and the 
samples were transferred immediately to -80°C. After one week at -80°C the cells were 
transferred to liquid nitrogen containers and stored at -196°C. In order to thaw cells, 37°C warm 
growth medium was added to the frozen cells with a Pasteur pipette. One washing step was 
performed in 10 ml growth medium to remove the DMSO. After that the cells were seeded in 
fresh medium in a cell culture flask. 
 
2.2.6   5-Azacytidine treatment 
The cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum. 
Ninety six hours after treatment with 20mM of 5-aza-2'-deoxycytidine, cells were harvested and 
subjected to subsequent experiments. 
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3.  Results 
 
 
3.1  Chromosomal rearrangements on 9p in different tumor types 
 
To investigate and characterize the precise genomic rearrangements throughout 9p, fine tiling 
custom array CGH (comparative genomic hybridization) technology was applied on four 
different tumor types including glioblastoma/glioma, neuroblastoma (NB), colon cancer (CC) 
and breast cancer (BC). Sixty-bp probes where applied for the entire 9p arrays and custom 
design arrays containing FRA9G, CDKN2A and FRA9C, with intervals of 40 and 80 bp, 
respectively. Due to the high resolution of the probes, we were able to define the precise 
location of the breaks and genomic alterations on the target sequence. The number of probes 
was enough to cover the whole length of 9p sequence. In addition to array-based experiments, 
fluorescence in situ hybridization (FISH) was performed to validate the results obtained from 
the aCGH experiments. 
 
 
3.1.1 Copy number changing profiles 
 
Copy number changes are the most frequently known type of human structural genomic 
variations. They comprise gains and losses of DNA fragments that are generally 500 bp, or 
longer, in length (Gokcumen and Lee 2009). 
The aCGH output files of all the cell lines from four different tumor types were loaded to UCSC 
Genome Browser to analyze their copy number changes on entire 9p. Figure 1-1 overviews the 
copy number changes of 9p region in GB/glioma (A172, H4, Hs-683, U138-MG, U-373 MG 
and U-87 MG), NB (SK-N-BE2C, CHP-134, Kelly, LAN-6, NGP and Vi-856,), CC (HDC-54, 
HDC-57, HDC-73 and HDC-87) and BC (BT-20, COLO-824, MCF-7, MDA-MB-436, MX-1 
and SKBR3). The copy number changes of each cell line are shown as losses (red) and gains 
(green) on individual tracks. The top position along the chromosome 9 is indicated in Mb scale. 
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gain (green) an9py number changes along the short arm of chromosome 9 in different cancer cell lines. On the 
deogram of chromosome 9. The output data files from array CGH experiments of 9p arm are loaded 
 and copy number changes of individual cell line are displayed on each track. The x axis above the 
ts position along the length of the chromosome in Mb scale. Chromosomal aberrations are shown as 
d loss (red). Custom tracks for (A) glioma/GB, (B) NB, (C) CC, and (D) BC cell lines are displayed. 
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Figure 3-1.A displays the copy numbers along 9p in GB/glioma cells. All six cell lines show 
copy number changes on their 9p, including clusters of loss in a region located in between 20 to 
25 Mb from telomere. In H4 cells, other regions of copy number loss were observed at 29, 16-17 
and 10-12 Mbs. U138-MG cells also contained a region of loss at 28 Mb. 
In NB cells (Fig. 3-1.B) different regions of losses were observed as well. All six NB cells 
shared a copy number loss in the sequence from 28 to 30 Mb. In Kelly, LAN-6 and Vi-856 there 
were also losses on distal 9p, at 10, 4 and 7 Mb, respectively. 
Colon cell lines, HDC-54 and HDC-73, showed a large fragment of loss which started from 
approximately 24 Mb from telomere and extended to the distal end of 9p (Fig. 3-1.C). There 
were also homozygous copy losses within this large region of loss in these two cell lines.  
HDC-73 cells also showed a region of copy number loss spanning region of 29 to 31 Mb from 
telomere. 
All six BC cells showed copy number changes, including losses and gains, on their 9p arm (Fig. 
3-1.D). BT-20 cells had copy gains on very distal (locations 2 and 8 Mb) and proximal (point 34 
Mb) 9p. COLO-824 cells had a large fragment of copy gain starting approximately 16 Mb from 
telomere extending all along 9p to the distal end. MX-1 cells had a gain region spanning from 
position 12 to 20 Mb from telomere.  
Overall, the copy number profiles along 9p show an individual pattern of alterations in different 
tumor types. Furthermore, most of the copy numbers were losses rather than gains. 
 
 
3.1.2  FRA9G, CDKN2A and FRA9C are breakpoint-clustering loci on 9p  
 
High-resolution aCGH, allowed us to precisely define the location of overall breakpoints 
occurring along short arm of chromosome 9 and therefore to estimate the impact of a particular 
CFSs on genomic alterations along 9p. To achieve this, 29 cell lines from different types were 
applied, including 6 glioma/GB cell lines (A172, H4, Hs-683, U138-MH, U-373 MG and U-87 
MG), 9 NB cell lines (SK-N-BE2C, SK-N-FI, SH-EP, HD-N-33, CHP-134, Kelly, LAN-6, 
NGP, Vi-856,), 5 CC (HDC-54, HDC-57, HDC-73, HDC-75, HDC-87) and 9 BC (BT-20, 
COLO-824, MCF-7, MDA-MB-436, MX-1, T47D, MX-1, MFM-223, SKBR3). 
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In glioma/GB cells (Fig. 3-2), the percentage of the breakpoints within FRA9G and FRA9C were 
12% and 2.5%, respectively. Forty five percent of the total breakpoints were located in the 
region in between the two CFSs, and clustered within the CDKN2A locus.  
In NB cells (Fig. 3-2), FRA9C contained a large cluster of the breakpoints within its sequence 
(38% of total breaks). FRA9G in NB cells comprised a tital of 10% of all breakpoints. The 
region in between the two CFSs in NB cells contained 27% of the breakpoint, from which 
almost all of them clustered in CDKN2A locus.  
In CC, no breakpoints were detected within either FRA9G or FRA9C, and 37% of the breakages 
occurred in the region flanked by the two CFSs, forming a cluster on distal side of CDKN2A 
locus. Colon cancer presented less number of breakpoints along 9p, compared to the other three 
groups.   
In BC, the percentage of the breaks within FRA9G and FAR9C were 5% and 4%, respectively. 
Only 16% of total breaks occurred in the region between the CFSs. Instead, three clusters of 
breakpoints were observed in these cells, one on proximal 9p (p13.3), one on central 9p (p22.3) 
and the other one on distal 9p (p24.4) 
These results propose various non-random clusters of breakpoints along 9p of different tumor 
cell types. In glioma/GB cells, FRA9G and CDKN2A locus comprise majority of the breaks. In 
NB, regions spanning CDKN2A and FRA9C contain the clusters of breakpoints. In CC more 
than one third of the breaks occur between the two CFSs, nearby CDKN2A region. Breast cell 
lines show a more evenly distributed pattern of breakpoints, containing more than half of their 
breaks (56%) on distal part of 9p, whereas in glioma/GB, NB and CC, proximal 9p is the main 
target for breakages on 9p. 
Altogether, these data demonstrate non-random involvement of FRA9G, and FRA9C in 
instability events on 9p of different tumor cells. While FRA9G is predominantly involved in 
glioma/GB rearrangements, FRA9C is the main target of genomic alterations in NB cells. 
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Figure 3-2. Schematic diagram for distribution of the breakpoints along 9p arm in four different tumor cell 
types. On top is the ideogram of the 9p arm. Location of FRA9C, CDKN2A and FRA9C loci are indicated by color 
bars.  The arrows represent the precise location of each breakpoint observed in aCGH results. The percentages of 
the breakpoints on 9p within FRA9G and FRA9C are written next to their location. The percentage written in 
between FRA9G and FRA9C represents the breakpoints occurring in the region flanked by the two CFSs. In three 
tumor cell types, including glioma/glioblastoma, neuroblastoma and colon, the majority of the breakpoint occurs 
within FRA9C, FRA9G and the region in between the two CFSs. Only in breast cancer cells, more than half of the 
breakpoints present to be on distal 9p. 
 
 
3.1.3  FRA9G, CDKN2A and FRA9C demonstrate multiple rearrangements within 
their sequence in tumor cells 
 
To explore precisely the nature of genomic alterations occurring within the sequence of FRA9G, 
CDKN2A and FRA9C, aCGH data from the region spanning the three loci sequences and the 1 
Mb regions flanking them were taken for analysis. High-resolution custom array allowed 
detecting copy number changes encompassing large genomic fragments, as well as micro-
deletions and micro-duplications. 
In addition, FISH validation was performed for some cases to confirm the rearrangements 
observed in array results. 
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3.1.3.1 FRA9G  
 
Seven out of 29 cell lines presented rearrangements within their FRA9G sequence. These cells 
included one glioblastoma (U-373 MG), one glioma (H4), three NB (SK-N-BE(2)C),  
SK-N-FI, Vi-856), and two BC (MX-1, COLO-824). As examples, aCGH plots of four cell lines 
representing the genomic alteration in this region are shown in Figure 3-3. 
H4 cells showed two breakpoints distal to FRA9G. This resulted to a deleted region of 
approximately 1 Mb (Fig. 3-3.A). In U-373 MG cells, two breakages distal to FRA9G were 
detedted, leading to the duplication of an approximately 500 kb fragment (Fig. 3-3.B). In SK-N-
FI cells, four breakpoints were found within and flanking FRA9G, resulting to heterozygous 
deletion of two fragments of less than 1 Mb in size (Fig. 3-3.C). COLO-824 cells showed four 
breakpoints within FRA9G which led to two micro interstitial deletions within the CFS sequence 
(Fig. 3-3.D). Altogether, a combination of various rearrangements, including deletion and 
duplication of small or large fragments of chromosome, either within or in the vicinity of 
FRA9G, were observed in different tumors. 
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Figure 3-3 Array CGH plots representing rearrangements in FRA9G sequence in (A) H4, (B) U-373 MG,  
(C) SK-N-FI and (D) COLO-824. On top is the position along the length of chromosome 9. The green bar 
corresponds to the location of FRA9C. The red circle and arrows indicate the location of the deletion, duplication 
and breakage sites occurring within or in the vicinity of FRA9G. 
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3.1.3.2 CDKN2A 
 
Fourteen out of 29 cell lines presented genomic alterations either within or in the vicinity of 
their CDKN2A locus. These cells include all the glioma/GB cells (A-172, U-87 MG, U-373 MG, 
U-138 MG, Hs-683, H4), five NB (LAN-6, SK-N-FI, SK-N-BE(2)C, SH-EP, Vi-856), one CC 
(HDC-54) and two BC (MCF-7, COLO-824). The aCGH plots of four cell lines in Figure 3-4 
represent the arrangements observed within CDKN2A in the cells. 
U-373 MG cells showed a micro-deletion in the CDKN2A gene (surrounded in red circle in Fig. 
3-4 A), which occurred, in addition, within a larger deleted fragment in this region. In SH-EP 
cells, a similar pattern of a homozygous micro-deletion within a previously heterozygous 
deleted region was observed in a fragment that spanned over the CDKN2A locus, but the micro-
deletion occurred not within, but distal to CDKN2A (Fig. 3-4 B). Moreover, there was a micro-
deletion 444 kb proximal to CDKN2A. In MCF-7 cells, the occurrence of three breaks led to the 
deletion of a region that spanned over CDKN2A sequence (Fig. 3-4 C). In BT-20 cells, a 65-kb 
deletion spanned over the CDKN2A sequence (Fig. 3-4 D). A micro-duplication was also 
observed in these cells distal to CDKN2A. 
Overall, more than half of all cell lines shows alterations in the region where CDKN2A is 
located. All the rearrangements in CDKN2A sequence were deletions. 
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Figure 3-4 Array CGH plots representing rearrangements in CDKN2A sequence of (A) U-373 MG,  
(B) SH-EP, (C) MCF-7, (D) BT-20. On top is the position along the length of the chromosome 9. The gray bar 
corresponds to the location of CDKN2A. The red circle and arrows indicate the location of the deletion, duplication 
and breakage sites occurring within or in the vicinity of CDKN2A. 
 
 
 
3.1.3.3  FRA9C 
 
Out of 29 examined cell lines, 11 demonstrated genomic alterations within or in the vicinity of 
their FRA9C sequence. These cells included one glioblastoma (U-138 MG), six NB (LAN-6, 
Kelly, SK-N-FI, SK-N-BE(2)C, SH-EP, Vi-856), two CC (HDC-54, HDC-73) and two BC 
(MX-1 and COLO-824). Array plots for LAN-6, SH-EP, COLO-824 and Kelly are presented in 
Figure 3-5. 
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Figure 3-5 Array CGH plots representing rearrangements in FRA9C sequence of (A) LAN-6, (B) SH-EP,  
(C) COLO-824, (D) Kelly. On top is the position along the length of the chromosome 9. The orange bar 
corresponds to the location of FRA9C. The red arrows indicate the location of the deletion and break points 
occurring within or in the vicinity of FRA9C. 
 
 
In LAN-6 (Fig. 3-5.A), a break occurred approximately 120 kb proximal to FRA9C and resulted 
into a heterozygous deletion which extended for almost 16 Mb to the distal end of 9p. SH-EP 
cells showed a 51 kb deletion within their FRA9C (Fig. 3-5.B). The deleted fragment seemed to 
be a heterozygous loss. In COLO-824 cells, a break occurred within FRA9C, which 
subsequently led to a duplicated fragment that extended over the distal side of the breakage and 
spanned the whole FAR9G sequence, as well (Fig. 3-5.C). In total, COLO-824 presented 
multiple and very complex rearrangements on the short arm of chromosome 9. Kelly cells 
showed rearrangements within FRA9C (Fig. 3-5.D). Two regions of loss were detected in this 
cell line, each to be 93 kb and 77 kb in size. 
Together, analysis of FRA9C sequence revealed frequent occurrence of rearrangements within 
or in the vicinity of this region in different tumor cells. 
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3.1.3.3.1   Fluorescence In situ hybridization (FISH) confirms aCGH data 
 
To validate aCGH findings, FISH analysis using BAC clones spanning the FRA9C region were 
performed on a number of cell lines that were earlier subjected to aCGH. BAC clones from 
RP11- library that was used for our in situ experiments are listed in the Table 3-1. 
 
              Table 3-1.  List of the BAC clones with their chromosomal band location and corresponding locus 
 
BAC clone                        chromosomal location                     Corresponding locus 
   
RP11-29P12 
 
RP11-30O14 
                                                                  
RP11-29M23 
 
RP11-159L16 
                          
RP11-450P11 
                                                                                       
RP11-83O12 
         
RP11-438B23 
              
RP11-421H8                                                    
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Figure 3-6. Fluorescence In situ confirmation of rearrangements in LAN-6 cells. The chromosomes were 
counterstained with DAPI. Two-color FISH for LAN-6 cells using BACs RP11-159L16 (yellow) and RP11-450P11 
(green). Heterozygous deletion of the green signal (indicated by red arrow) corresponds to FRA9/LINGO2 region. 
 
 COLO-824 
Three BAC clones were applied for in situ hybridization in COLO-824 cell line. BACs RP11-
438B23 and RP11-83O12 spanned within the FRA9C/LINGO2 region and were labeled with 
Cy3 (red) and FITC (green), respectively. BAC clone RP11-30O14, which was the most 
centromeric to the other two, corresponded to a proximal adjacent sequence to FRA9C and was 
labeled with DEAC (purple). Figure 3-7 shows a duplicated signal for all the three BACs. This 
is in accordance to the previous M-FISH karyotyping data in our lab which showed that 
complex genomic rearrangements affect 9p and that there are four derivative chromosomes, with 
material of 9p in all analyzed metaphases of COLO-824 cells. In addition, one extra signal from 
BAC RP11-438B23 (red) was observed. These FISH results confirm the amplification events 
which were earlier detected in aCGH results. 
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Figure 3-7. Fluorescence In situ confirmation of rearrangements in COLO-824 cells. The chromosomes were 
counterstained with DAPI. Three-color in situ hybridization performed using BACs spanning FRA9C/LINGO2 
region revealed amplification of the signals from all the three BAC clones. BACs RP11-83O12 (green) and RP11-
30O14 (purple) showed a duplication represented by four signals corresponding to a aneuploidy karyotype of this 
cells. There is one extra signal for BAC RP11-438B23 (red) which is indicated by red arrow. 
 
HDC-73  
In the aCGH analysis, a region of deletion proximal to FRA9C was detected in HDC-73 cells. 
To confirm this, three-color in situ hybridization was performed using BAC clones spanning 
from the distal to the proximal region of the deletion. BAC clones RP11-29P12 corresponding 
to the normal region distal to the deletion, and RP11-421H8 spanning a region proximal to the 
deletion were labeled with Cy3.5 (pink) and Cy5.5 (light blue) respectively. RP11-29M23, 
which was labeled with Cy5 (yellow), was used to represent the region of deletion. The FISH-
mapping studies in our lab had already revealed a triploid karyotype for HDC-73 cells, and as is 
shown in Fig. 3-11.A, this phenomenon was observed for BACs RP11-421H8 and RP11-29P12. 
In two out of three spots, which are indicated by red arrows in Figure 3-8, the yellow signal 
from RP11-29M23 is missing. This confirms the loss of deleted region previously observed in 
the array data. 
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CDKN2A showed to be a main target of rearrangements in all four types of cell lines. Among 
the 29 cells analyzed in aCGH experiments, 48% (14 out of 29) showed damage in p16. The 
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Figure 3-8 Fluorescence In situ confirmation of rearrangements in HDC-73 cells. The chromosomes were 
counterstained with DAPI. Three BACs including RP11-29P12 (pink), RP11-421H8 (light blue) and RP11-29M23 
(yellow) were used on metaphases of HDC-73 cells. According to the triploid karyotype of HDC-73 cells, our 
analysis showed three spots containing pink and light blue colors representing RP11-29P12 and RP11-421H8, 
respectively. However, in two of three spots, the yellow signal of RP11-29M23 was missing. This is exactly 
corresponding to the region of deletion previously detected in array experiments. 
 
 
 
3.1.4 Differentiated pattern of 9p rearrangements in four tumor types 
 
3.1.4.1 Frequencies of involvement of target regions of 9p in chromosome alterations 
 
Array CGH data for the group of 29 cell lines (6 glioma/GB, 9 NB, 9 BC and 5 CC) were 
quantified for rearrangements on their short arm of chromosome 9. Out of 29 cell lines, 22 
(73%) demonstrated rearrangements on 9p. Glioma/GB cell lines showed the highest rate of 
aberrations on 9p, 100% (Fig. 3-9). The other three groups, including NB, CC and BC cells, 
each presented 9p aberrations with rates of 66%, 40%, and 66%, respectively.  
FRA9G rearrangements were observed in all four types of cells which comprised of 26% of all 
the examined cells. FRA9G aberration rates in glioma/GB, NB, CC and BC cells was 33%, 33%, 
0% and 22%, respectively. In 70% of the cells, the aberrations occurred within FRA9G.  
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ts in FRA9C in different groups was 16% (GB/G), 66% (NB), 40% (CC) and 22% 
 in the vicinity of CDKN2A and the two CFSs (FRA9G and FRA9C), in various tumor 
igure 3-9.  Percentage of overall rearrangements along entire 9p and also within or in the vicinity of 
RA9G, CDKN2A and FRA9C in g /GB, NB, CC and BC 
arrangements. The graph presents t a revealed by om aCGHs (with the resol ion of 40 and 80 bp). 
highest percentage was presented by glioma/GB cells, which was 100% (Fig. 3-9). NB cells also 
had a high damage in p16 gene (55%). Colon cell lines and BC displayed 20% and 11%, 
respectively. 
FRA9C was rearranged in 40% of all the four types of cells examined. The total number of 
rearrangemen
(BC) (Fig. 3-9). From all the cells presenting rearrangements in the FRA9C region, two thirds 
(65%) of the damage occurred within the CFS. The rest showed aberrations in the vicinity of 
FRA9C. 
Altogether, aCGH and FISH results indicate a frequent occurrence of rearrangements either 
within or
types. In particular, FRA9G and CDKN2A in both glioma/GB and NB cells, and FRA9C in NB 
present a predominant involvement in genomic rearrangement. These rearrangements include 
both losses and gains, which vary in size from very small regions from a few kliobases to large 
fragments of several Mb from the chromosome. 
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 order to have more accurate validation of the results obtained from the aCGH experiments, 
a larger number of cell lines. Array CGH 
igure 3-10.  Percentage of overall rearrangements along entire 9p and also within or in the vicinity of the 
ree cluster forming loc G, CDKN2A and FRA9C in database aCGH experiments. Y axis represents 
he percentage of rearrangements. The graph displays tage of rearrangements ba n analysis of the aCGH 
sults obtained from the database (group of 173 cell lines, with the resolution of 1 Mb). 
btained from the database and analyzed (Fig. 3-10). In 68% of all cell lines, rearrangements on 
. 
lteration in FRA9G, CDKN2A and FRA9C. 
3
 
In
the same quantification analysis was further applied to 
data, (with the resolution of 1 Mb) were retrieved from database (COSMIC project) and 
investigated for the overall rearrangements on total 9p, and FRA9G, CDKN2A and FRA9C in 
particular. 
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A group of 173 cell lines, including 59 (glioma/GB), 37 (NB), 32 (CC) and 45 (BC) were 
o
9p arm was observed. Almost 90% of the glioma/GB cells showed rearrangements on 9p. NB, 
CC and BC cells exhibited 9p rearrangement rates of 55%, 60% and 75%, respectively.  
No rearrangements in FRA9G was observed in NB cells while glioma/GB, CC and BC cells 
presented 5%,  5% and 10%  rearrangements, respectively. 
As for CDKN2A, nearly 80% of glioma/GB cells showed deletion in CDKN2A locus. This 
number was 20% for NB, 15% for CC and 28% for BC cells
FRA9C was rearranged in more than 40% of the NB cells, whereas this value was 25%, 15% 
and 15% for glioma/GB, BC and CC, respectively. 
To sum up, applyin the analysis to the aCGH data of a larger number of cell lines (173) obtained 
from the database, presented a similar pattern for a
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RA9C and CDKN2A were observed. Upon close look on the mode of deletion in these two 
 
 
 
 
 
 
Fig 3-11.  FRA9C involvement in CDKN2A deletion. (A) Shows the array CGH plot for LAN-6 cells. The 
h gous deletion of FRA9C which occurs due to a break within th ag cus d er y 
d ed region on the distal side, in which a second hit of breakage events uld lead to homozygous deletion of 
ase were explored in order to know 
 the examples observed in aCGH results were more than just a coincidence, and if so, how 
The differences seen in a few cases could be due to the lower resolution of the arrays used in 
producing the results of database, and therefore probably micro-deletion and duplications were 
not detected in those experiments. 
 
 
3.1.4.1 Breakage at FRA9C co
 
While analyzing rearrangements occurring in 9p, cell lines bearing rearra
F
regions in a same cell line, we encountered samples in which a heterozygous deletion in FRA9C 
was extended to a homozygous deletion of CDKN2A gene (Fig. 3-11.A). In fact, it seems that 
this occurs in two steps in the region. In one step, a breakage ocurrs in the fragile site which 
makes a heterozygous deletion, and in the other step, occurrence of a breakage leads to the 
complete deletion of the gene locus on the chromosome. 
 
Glioma/G
 
A
eterozy
elet
e fr ile lo , led to a istal het ozygousl
 co
CDKN2A locus. (B) The graph presents the percentage of the different cancer cells (data obtained from the 
database) that demonstrated such a model for their CDKN2A deletions. 
 
 
A larger number (173 cell lines) of array data from the datab
if
often they ocurr in cancer cells. The results are presented in Figure 3-11.B. In NB cells, half of 
the CDKN2A homozygous deletion cases were similar to the pattern observed earlier. In nearly 
20% of the glioma/GB cells, deletion of CDKN2A was derived directly from breakage in 
 61
 
Results 
 
 
 
ns indicate an active role of FRA9C in homozygous deletion of 
  
                                                       
usceptibility candidate genes on 9p; CFS genes 
or-associated susceptible loci along 9p, a total of thirty cell lines (grouped in four 
ccording to their aCGH results) showed breakpoints or regions 
f them occurred in the region 
as the 
observed in half of the glioma/GB cell lines.  
FRA9C, too. In CC and BC, there was either very little (3%) or no occurrence of this 
phenomenon, respectively. 
Collectively, our observatio
CDKN2A locus in NB cells.   
 
  
     
3.2   Identification of cancer s
as novel candidates  
 
To explore tum
types, including NB, glioma/GB, CC and BC) were inspected for the chromosomal aberrations 
within the genes located on 9p.  
To achieve this aim, genes that (a
of losses/gains either within or in the vicinity of their sequence were considered to be affected. 
Then, genes presenting genomic alteration in more than one cell line were taken into 
consideration. Genes that are only altered in one cell line were excluded. The results of the 
evaluation are summarized in a schematic diagram in Figure 3-12. 
From total gene alterations considered for all the cell lines, 70% o
between FRA9C and FRA9G. This rate was 75% and 87% for neuroblastoma and glioma/GB 
cell lines. There were few numbers of alterations on 9p of colon cell lines, from which almost all 
of them occurred between the two fragile sites. Breast cell lines showed the most scattered 
pattern of alteration points, presenting less than half of them in between FRA9G and FRA9C. 
Genes residing in this region which showed highest occurrence of aberrations included, 
MTAP/CDKN2A, LINGO2, BNC2, IFN gene cluster, CNTLN and ELAVL2, respectively.  
Furthermore, each group of cell lines was separately investigated for the specific genes 
target for aberrations. LINGO2 showed to be altered in almost 66% of all the NB cell lines. This 
score comprised 45% 33% and 33% of NB cells for MTAP/CDKN2A, CNTLN and BNC2, 
respectively. In GB/Glioma cell lines, MTAP/CDKN2A and IFN gene cluster presented highest 
range of alteration, 100% and 85%, respectively. In addition, alterations in ELAVL2 gene was 
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oximal part of 9p, specifically the region lying in 
etween the two fragile sites, is a hotspot for gene alterations in cancer cells. Genes located in 
s on 9p in NB and 
 
Collectively, our analyses propose that the pr
b
this region, including, ELAVL2, CDKN2A, MTAP, INF gene cluster and BNC2, which are 
known to have critical functions in different biological processes, presented high levels of 
damage in various tumor cells. This suggests that these genes may be candidates for tumor-
susceptibility loci on 9p. However, not all of these genes are contributing the same level of 
rearrangements in different cell types. CDKN2A, MTAP and INF gene cluster appear to be 
mostly deleted in NB and glioma/GB cells, whereas ELAVL2 shows to be more involved in 
glioma/GB cells. And BNC2 gene damage is more highlighted in NB cells.  
Furthermore, based on the results in this study, it is suggested that CFS genes of this region, 
including CNTLN and LINGO2, as new candidate tumor-susceptibility gene
GB/Glioma. The significance of FRA9G/CNTLN and FRA9C/LINGO2 loci in 9p rearrangement 
events attracts more consideration when their damage frequency is compared to that of 
CDKN2A/p16 locus, which has been long been reported in literature as a main target of 
rearrangement events in various tumors. As is presented in Table 3-2, FRA9G and FRA9C show 
15% damage when calculated in all cell lines together, and considering the length of the two 
CFSs which comprise less than 3% of whole 9p, we propose that FRA9G/CNTLN and 
FRA9C/LINGO2 not only play an important role in rendering instability on 9p, but are also 
frequent targets of such instabilities in the region.  
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FRA9C shows to have the most affected genes within it. FRA9G and FRA9C related genes, as well, are highly 
damaged in NB and glioma/GB cells. 
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MCF-7
MFM-223
MDA-MB-436
SKBR3
T47D
MX-1
BT-474
BT-20
COLO-824
Breast Cancer
HDC-57
HDC-75
HDC-87
HDC-73
HDC-54
Colon Cancer
Vi-856
SHEP
HD-N-33
SK-NF-I
SK-N-BE(2)C
CHP-134
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Neuroblastoma
U-138 MG
A-172
U-373 MG
Hs-683
U-87 MG
H4
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CDKN2AFRA9CFRA9G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-2. Twenty nine cell lines tested for 9p rearrangements using aCGH-based analysis, presented by the 
equency of rearrangements in three loci, including FRA9G, FRA9C and CDKN2A. Red boxes indicate the 
amaged sequence of each locus in individual cell lines. Comparison of the number of damage in CDKN2A locus, 
s a well-known frequent target for genetic alteration, to that of FRA9G and FRA9C suggests these two CFSs as 
ovel candidate tumor-susceptibility loci in different tumor cells.    
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d
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3.2 Sequence analysis of unstable regions of 9p 
 
Since it has been proposed that DNA sequences within CFSs could count for the reason of 
fragility observed in their region, we analyzed the DNA sequence of the three breakpoint-
clustering regions which were already identified in our aCGH results. 
 
 
3.3.1. DNA repeat composition and flexibility 
 
Earlier, three regions of breakpoint clusters, including FRA9G, CDKN2A locus and FRA9C were 
shown to contain the majority of breakpoints within or nearby their sequence. To analyze the 
DNA sequence of those regions for their DNA repeat composition and flexibility, the 1 Mb 
cores of the clusters, as well as their centromeric and telomeric flanking regions of the same 
size, were taken and subjected to RepeatMasker and TwistFlex programs. 
The total DNA repeats that were analyzed for the three clusters of breakpoints were composed 
of MIR (1.9%, 3.5%, 3.6%), ALU (5.2%, 4,6%, 3,6), LINE1 (17.1%, 25.3%, 17.3%), LINE2 
(2.7%, 3.8%, 3.7%), LTR ( 6%, 10.1%, 6.4%) and DNA elements (3.6%, 2.7%, 3%) for 
FRA9G, CDKN2A and FRA9C regions, respectively (Fig. 3-13.A). The CG content of the 
unstable regions showed similar ranges to the non-fragile genome. For FRA9G, CDKN2A, 
FRA9C and non-fragile regions, 38.3%, 38.1%, 36% and 38% CG content was obtained, 
respectively. 
The comparison of DNA repeat elements in the three clusters of breakpoints did not show a 
significant difference between the core regions and their flanking sequences and also the  
non-fragile genome.  
Then, DNA helix flexibility in breakpoint-clustering regions was calculated. The outcome 
revealed an average of 3, 6.5 and 7.5 flexibility peaks per 100 kb for FRA9G, CDKN2A and 
FRA9C-containing clusters, respectively. Non-fragile genome showed approximately 4  
Flex peaks per 100 kb (Fig. 3-13.B).  
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Figure 3-13. DNA sequence analysis of three breakpoint-clustering regions on 9p. Each cluster was divided 
into three regions of 1 Mb in size and named after the core region of instability within them, including FRA9G, 
CDKN2A and FRA9C. The analysis was done separately for the 1 Mb core sequence and its 1 Mb flanking 
sequences.  (A) Shows the repeat composition of the 1 Mb-sequence in the core of each cluster, as well as 1 Mb 
flanking sequences of each cluster ("tel" for telomeric side and "cent" for centromeric side), compared to that of 
non-fragile regions of the human genome. X axis represents the percentage of each element. On the top, the 
percentage of CG content for each group is indicated. No significant differences were observed between and within 
the four groups of sequences.  (B) The number of flexibility peaks within the three breakpoint-clustering regions 
and human genome. FRA9C and CDKN2A-containing regions presented higher number of peaks compared to 
FRA9G and human genome. 
 
The 1Mb-sequence of each breakpoint clustering region was studied more closely as windows of 
100 kb in size. In all the three clustering regions, there was one single 100 kb window that 
contained the majority of the breakpoints in that region. In addition, a window of region-of-no-
flexibility peaks was identified that had no breaks within its sequence. All the four 100 kb 
sequences (three from breakpoint clusters and one from the window of no breaks) were picked 
up and subjected to repeat elements analysis.  
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Figure 3-14. DNA sequence analysis of the 100 kb windows within the breakpoint clusters. These 100 kb 
windows of FRA9G, CDKN2A and FRA9C showed to have the majority of the breakpoints within the clusters. The 
region of no peaks was a 100 kb window within which no breakpoints or flexibility peaks were observed. 
 Comparison of (A) DNA repeats composition, (B) number of flexibility peaks and (C) number of equal or more 
than 5 perfect AT/TA repeats of the described windows are displayed. (A) Except from LINE1 elements in FRA9G 
window, and DNA elements in FRA9C window, no other distinct features were observed in different regions. (B) 
Number of flexibility peaks in CDKN2A and FRA9C showed higher rates than proposed for CFSs average, which is 
said to be 5. (C) Number of equal or more than 5 perfect AT/TA repeats was also much higher in CDKN2A and 
FRA9C window, compared to that of FRA9G and region of no peaks.  
 
The results for FRA9G, CDKN2A, FRA9C windows and the window of no FlexPeaks were MIR 
(0.2%, 1.9%, 2.6%, 2%), ALU (3.9%, 7.7%, 4%, 4%), LIINE1 (59.2%, 22.8%, 6%, 20%), 
LINE2 (3.1%, 3%, 7%, 4%), LTR (7.3%, 21.6%, 7.6%, 5.6%) and DNA elements (2%, 2.3%, 
29%, 1.4%), respectively (Fig. 3-14.A). The 100 kb-window within FRA9G revealed almost 
threefold LINE1 elements content compared to the other three windows. DNA elements content 
in FRA9C window was relatively higher compared to the FRA9G and CDKN2A windows and 
also the single non-fragile genome sequences. Other repeat elements showed varied rates in 
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different sequences and no significant differences among them were observed. In addition, The 
CG content of the four windows did not present to be a significant feature (Fig. 3-14.A). 
The helix flexibility content of the 100 kb windows of FRA9G, CDKN2A and FRA9C was 
explored and the results showed 4, 14 and 10 flexibility peaks for each of them, respectively 
(Fig. 3-14.B). The number of peaks in CDKN2A and FRA9C windows was even much higher 
than the average that has been proposed for aphidicolin-induced common fragile sites (5 peaks 
per 100kb). This indicates that helix flexibility is an important element in the fragility of the 
CDKN2A and FRA9C regions. 
High number of flexibility peaks influences chromatin condensation process and increases the 
susceptibility to fragility. Moreover, it has been suggested that AT/TA perfect repeats within a 
fragile site can efficiently stall the replication fork and consequently result in instability. 
Comparison the frequency of equal or more than 5 perfect AT/TA repeats in the three regions of 
breakpoint cluster and the single region of no breaks and FlexPeaks, revealed recurrent repeats 
within CDKN2A and FRA9C –located region (Fig. 3-17.C). The high number of flexibility peaks 
and AT/TA perfect repeats in these two regions may be of critical importance in the instability 
observed within them. Whereas, both FlexPeaks and AT/TA perfect repeats within FRA9G-
located region present much less degrees than that of other two fragile regions, they are 
relatively similar to what is observed in the non-fragile sequence.  
 
In conclusion, DNA sequence analysis revealed a variation in DNA repeat composition of less 
stable regions, among the unstable regions of 9p and also between them and their flanking 
sequence. This did not give any clue to the nature of their susceptibility to breakages. Only 
regarding flexibility peaks, clusters in the region spanning FRA9C and CDKN2A presented a 
higher number of peaks in comparison to FRA9G and human genome.  
 
3.3.2 Segmental duplication (SD) and copy number variation (CNV) 
 
The segmental duplications, which might range from only a few to hundreds of kilobases, share 
a high degree of sequence identity and have been associated to chromosomal rearrangements in 
recent primate evolution and instability in human carcinoma cells. In order to estimate the SD 
content of the region of high instability on 9p and to estimate SDs involvement in 
rearrangements on 9p, distribution of segmental duplications (SDs) along the proximal 9p 
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region which spanned over the three breakpoint clusters was analyzed based on UCSC genome 
database (Fig. 3-15). A high content of SDs within FRA9C/LINGO2 locus, as well as in a 
telomeric vicinity of CKNA2A, where IFN gene cluster resides was observed.  
A cluster of copy number variation was also observed within FRA9C sequence. 
 
CDKN2A FRA9G FRA9C 
\ 
 
 
 
 
 
 
 
 
 
 
Figure 3-15.  Distribution of segmental duplications (SDs) along the region of 9p of which clusters of 
breakpoints locate.  A high content of SDs is observed within and in the vicinity of FRA9C and CDKN2A loci. In 
the lower track, where CNVs along the region are displayed, there is also a population of CNVs for FRA9C locus. 
 
SDs analysis suggests that a high number of SDs within or in the vicinity of FRA9C and IFN 
gene cluster might be associated to the high frequency of instability observed in this region of 
various tumor cells. 
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3.4   Fragile site genes expression analysis  
 
Since FRA9G/CNTLN and FRA9C/LINGO2 loci demonstrate to be hot spots for genomic 
rearrangement events, one could envisage an important functional role for the genes located in 
these loci in normal and malignant cell procedures. Therefore, as the first step in characterizing 
their function, we explored expression of CFS genes, CNTLN and LINGO2 in normal and tumor 
cells.  
 
3.4.1 FRA9G/CNTLN expression; ubiquitous in normal cells, differentiated in 
tumor cells 
 
The expression of CNTLN was examined in various human tissues and cell lines.  
Reverse transcriptase-PCR analysis in twenty one tissues demonstrated that CNTLN was 
expressed in all human tissues including adipose, trachea, bladder, brain, cervix, colon, 
esophagus, heart, kidney, liver, lung, ovary, placenta, skeletal muscle, small intestine, spleen, 
testes, thymus, thyroid and breast (Fig. 3-16.A).  
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Figure 3-16. mRNA expression analysis for CFS gene CNTLN. (A) Shows the ubiquitous expression of CNTLN 
mRNA in human normal tissues. (B) Presents the quantification of CNTLN expression, in which normal ovary and 
cervix cells showed highest level of mRNA expression in normal human tissues. 
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In addition, real-time quantitative PCR experiments showed ovary and cervix to have the 
highest mRNA expression of CNTLN among normal human tissues (Fig.3-19.B). 
Expression of CNTLN was further investigated in human cancer cell lines. CNTLN expression 
was detected in seven out of the nine BC cell lines, including MX-1, T47D, BT-20, MDA-MB-
436, BT-474, SKBR3, and MCF-7 (Fig. 3-17.A). No CNTLN expression was observed in 
COLO-824 and MFM-223. Moreover, CNTLN was expressed in most of the glioma/GB cell 
lines examined in this study, including H4, Hs-683, A-172, U-138, and U-87 (Fig.3-17.B). 
CNTLN expression was not detected in U-373. 
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Figure 3-17.  CNTLN expression analysis in tumor cells, (A) breast cell lines and (B) Glioma/glioblastoma cell 
lines. RT-PCR results showed differential expression of CNTLN in these cells. 
 
 
These results indicate that CNTLN is ubiquitously expressed in human normal tissues. 
Moreover, differential expression of CNTLN in the cell lines implies aberration of this gene in 
some cancer cells. Such aberrations could be due to structural changes which were also earlier 
detected in the aCGH results. 
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3.4.2   FRA9C/LINGO2 expression; differential in normal and tumor cells 
 
LINGO2 expression in a range of normal human tissues was investigated. Expression of 
LINGO2 was observed in a few tissues, including brain, kidney ovary, placenta, prostate and 
testes (Fig. 3-18).  
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Figure 3-18.  LINGO2 expression in normal human tissues. RT-PCR results showed a differential expression of 
LINGO2 in a few number of normal tissues. 
 
As brain tissue was among the few tissues showing LINGO2 expression, the probable 
disturbance of the gene expression in brain associated cell lines (glioma/glioblastoma) was 
investigated. One glioma (Hs683) and one glioblastoma cell line (U-138) did not reveal 
LINGO2 expression (Fig. 3-19 A). To explore whether epigenetic silencing via methylation is 
the cause of expression inhibition in these two cell lines, LINGO2 expression was examined 
before and after cell treatment with 5-azacytidin. LINGO2 expression was reversed in Hs-683 
cells after methylation inhibition, whereas U-138 still showed no expression (Fig. 3-19 A). This 
observation is in accordance with the data achieved for U-138 in aCGH experiments earlier. In 
addition, In situ hybridization was performed to confirm the integrity of LINGO2 gene locus in 
Hs-683, and to prove the genomic aberration in U-138. BAC clones RP11-264J11 and RP11-
123J20 covering LINGO2 and CNTLN regions respectively, were applied and the expected 
duplicate signal of both BAC clones were observed in Hs-683 cells , whereas the signal from 
BAC RP11-264J11, which locates within the rearranged sequence in  U-138 cells was missing 
(Fig. 3-19 B). The lack of purple signals form BAC RP11-264J11 in U-138 cells is an indication 
of rearrangements in LINGO2 sequence and could explain the lack of LINGO2 expression 
observed in these cells. 
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Figure 3-19. LINGO2 Expression in glioma/GB and NB cells. (A) RT-PCR for LINGO2 expression in 
glioma/glioblastomacells, before and after treatment with azacitydine. Hs-683 and U-138 showed no LINGO2 
expression before azacitydine treatment. After methylation inhibition by azacitydine treatment, the expresseion was 
reversed only in Hs-683 and not U-138. (B) Fluorescence hybridization of LINGO2 sequence in Hs-683 and U-138 
cells showed the signal of BAC RP11-264J11 (purple) in Hs-683 (on right-hand side), and not U-138 cells (on left-
hand side). This is an indication of genomic rearrangements in this region of U-138 cells which could justify the 
lack of LINGO2 expression in these cells. (C) RT-PCR for LINGO2 expression in neuroblastoma cell lines. A 
differential pattern of expression was detected with expression mostly observed in MYCN-amplified cells  
(indicated by asterix on top). 
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LINGO2 expression was also investigated in NB cells. Twenty five NB cells were examined for 
LINGO2 mRNA, including NMR, TR14, WAC2, NBLS, LAN1, LAN2, NBS, LS, GIMEN, 
Vi856, CHP126, NLP, NB64, MHH-NB-11, SK-N-BE, SH-SY5Y, LAN5, Kelly, NGP, 
CHP134, N-BE(2)C, HDN33, SK-N-FI and SH-EP (Fig. 3-19 C). A differential expression of 
LINGO2 in NB cells was observed, with a tendency of expression mostly in MYCN positive 
cells (indicated in the figure by an asterix on top). 
In conclusion, LINGO2 shows a differential pattern of expression in normal tissues, as well as in 
the tumor cell lines. Also, there is an indication that epigenetic mechanism of hypermethylation 
could be involved in control of LINGO2 gene expression. 
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4.  Discussion 
 
 
One of the primary missions of cancer research is to discover candidate genes involved in tumor 
development. Chromosomal fragile sites (CFSs) are particularly sensitive to DNA breaks and 
are frequent sites of rearrangement or loss in many human cancers. Studies on the most 
expressed CFSs, FRA3B and FRA16D, have revealed that CFSs are the sites for deletion and 
loss of heterozygosity (LOH) in many cancers (Huebner and Croce 2001; Yang et al. 2002; 
Finnis et al. 2005; O'Keefe and Richards 2006). Common fragile sites are supposed to be the 
genomic regions which exhibit breakage at the very early stages of tumorigenesis (Bartkova et 
al. 2005; Gorgoulis et al. 2005; Halazonetis et al. 2008). Identification of CFS genes and their 
involvement in chromosomal rearrangements in different cancer types may lead to discovery of 
new cancer-susceptibility genes.  
The short arm of chromosome 9 is involved in genomic rearrangements in several types of 
cancer. Inversions, translocations, deletions and LOH on 9p have been reported in various 
cancers. Different regions on 9p have been reported to be targeted by these genetic aberrations. 
Several studies demonstrate the incidence of LOH, mainly on 9p21 region, in a variety of 
malignancies like neuroblastoma (Mora et al. 2004), lung cancers (Sawada et al. 2003; 
Shibukawa et al. 2009) and renal carcinoma (Grady et al. 2001; Sanz-Casla et al. 2003). Also 
deletions in regions 9p22-p24 have been repeatedly observed in wide range of tumors like breast 
cancer (An et al. 1999) and neuroblastoma (Giordani et al. 2002). In fact, these findings imply 
the involvement of even more than one region of LOH on 9p in many cancers.  
Two CFSs are located on 9p region. A study by Savelyeva and colleagues (Savelyeva et al. 
2001) demonstrated that heterozygous BRCA2 mutation carriers exhibit high levels of genomic 
instability on 9p23-24, including inversions, duplications and amplifications. This led to a 
proposition that there is a particular tendency of distal 9p to spontaneous instability, which 
could be possibly due to the presence of a fragile site in the vicinity of the aberration region. 
Finally, FISH mapping studies revealed FRA9G as a new CFS at 9p22.2 (Sawinska et al. 2007). 
There is also FRA9C which is listed in the databases as a CFS mapped on proximal 9p, and its 
precise location was not characterized until recently in a work done by Sawinska et al, (2008, 
unpublished). FRA9C lies on a region spanning distal 9p21.1 and 9p21.2 boundary. 
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In this study, the probable involvement of these two CFSs and their encompassing genes, 
FRA9G/CNTLN and FRA9C/LINGO2, in chromosomal rearrangement events on 9p is explored. 
 
 
4.1  FRA9C and FRA9G are frequently involved in 9p instability 
 
By applying aCGH technique, it is feasible to define the possible impact of FRA9G and FRA9C 
on the chromosomal aberrations on 9p. While overall 9p region rearrangements in all four cell 
types were approximately 73%, the damage rate presented in FRA9G and FRA9C (26% and 
40%, respectively) showed to comprise a significant part of this whole damage on 9p. In total, 
FRA9C showed higher degrees of aberrations compared to FRA9G.  
FRA9C was predominantly damaged in NB cells. In glioma/GB cells, although 100% of the 
cells had rearrangements on 9p, only less than 20% of them exhibited FRA9C alterations, 
whereas the rate of 9p and FRA9C alterations in NB were both almost similar and as high as 
70%. This observation implies the particularly important role of FRA9C in NB genetic 
aberrations on 9p. Analysis of a larger number of cell lines from the database, showed a similar 
pattern for FRA9C in NB cell lines. However, in general, rates retrieved from the database 
results were lower than what was observed in the custom aCGH data. This could be explained 
by the higher resolution of the custom array used in this study (40 bp), as compared to the 
probes used in producing the results in the database (1Mb).  
The total breaks occurring on the entire 9p in each tumor cell type were counted, and BC cell 
lines showed the highest number of breaks. However, it should be noted that due to very 
complex rearrangements observed in two BC cell lines, MX-1 and COLO-824, a considerable 
part of the breaks counted for breast tumors were actually coming only from these two cell lines, 
whereas there were cell lines showing no breaks on 9p, including MFM-223 and  
BT-474. So the assumption of BC having more breaks on 9p should be considered cautiously. 
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Type and number of cells 
 
total breaks 
 
FRA9G 
 
FRA9G-FRA9C 
 
FRA9C 
Glioma/Glioblastoma (6) 40 12% 45% 2.5% 
Neuroblastoma (9) 49 10% 27% 30% 
Colon Cancer (5) 26 0 37% 0 
Breast Cancer (9) 76 5% 16% 4% 
 
Table 5-1.  The percentage of overall breaks occurring within and in between the FRA9G and FRA9C.  
 
 
In NB, almost 30% of the breakpoints were within or in the vicinity of FRA9C (Table 5-1). In 
glioma/GB, regions flanking the vicinity of FRA9G contained 12% of the total breakpoint 
occurring in this type of cancer. The sequence of FRA9G and FRA9C which are 400 kb and  
800 kb constitutes only 2.5% of the whole 9p length. This suggests that there is a significant 
involvement of these two fragile sites towards genomic aberrations of this region. In addition, 
the majority of the breakpoints on 9p showed to occur in the 13 Mb region spanning over 
FRA9G and FRA9C sequence and the sequence flanked by these two CFSs. This region 
contained more than half of the breaks in NB, glioma/GB and CC (Table 5-1). This observation 
could be a supporting evidence for the important role of the two fragile sites in 9p instability.  
Apart from FRA9G and FRA9C sequence in NB and glioma/GB cells, a third cluster of 
breakpoints which were observed in these two types of cells located at CDKN2A and the region 
around it. Cyclin-dependent kinase inhibitor 2A (CDKN2A) is a tumor suppressor gene (TSG) 
which encodes for p16INK4A and p14ARF. The alterations of the CDKN2A/p16 have been reported 
in many cancers and its deletion is known to impair both the Rb and p53 pathways (Mora et al. 
2004). The observation which showed FRA9G and FRA9C as being largely active in 
rearrangement events on 9p, and the fact that the highly damaged locus of CDKN2A lies in 
between the two CFSs, further highlights the possible role of the two CFSs in the instability of 
this TSG. In fact, we observed the damage of CDKN2A locus in the cell lines that either one or 
both of the fragile sites were active in them.  
Based on the concordance of the location of fragile sites with chromosomal breakpoints, it has 
been hypothesized that common fragile sites may play a mechanistic role in the occurrence of 
chromosomal rearrangements observed in tumor cells (Yunis and Soreng 1984; Corbin et al. 
2002). In the results of this study, the breakage at FRA9C in three NB cell lines, including LAN-
6, SK-N-BE(2)C and Vi-865, led to the heterozygous deletion of a distal fragment which 
 78
 
Discussion
 
 
 
spanned over the CDKN2A locus. And in one of these cell lines, LAN-6, there was another 
interstitial deletion occurring with the deleted part, that led to the homozygous deletion of 
CDKN2A. Further investigations from the database reveal that a similar phenomenon also 
occurrs in the 50% of NB cells and 20% of glioma/GB cells. The observation that breakage at 
FRA9C coincides with deletion of CDKN2A, suggests the existence of an association between 
the two events, in terms of a possible mechanistic role for the CFS in alterations occurring in the 
TGS.  
In addition to the findings that suggest a contributory role of fragile sites in tumorigenesis, and 
given that CFSs are normal components of human chromosomes, one can assume that they also 
play a protective role against cancer. This function could be related to CFS genes. Common 
fragile site genes generally extend over long genomic regions and most of them contain several 
genes. Only six common fragile sites are restricted by single genes FRA1E/DPYD (Hormozian 
et al. 2007), FRA3B/FHIT (Ohta et al. 1996), FRA16D/WWOX (Ried et al. 2000; Bednarek et 
al. 2001), FRA13A/NBEA (Savelyeva et al. 2006), FRA9G/CNTLN (Sawinska et al. 2007) and 
FRA9C/LINGO2 (Sawinska et al, 2008, unpiblished data). Genes located at CFSs are highly 
susceptible to genomic instability especially in cancer cells. The studies on these genes in the 
context of their role in cancer development have revealed an important role for most of the large 
CFS genes as tumor suppressor (O'Keefe and Richards 2006; Smith DI 2006; Lukusa and Fryns 
2008). Several studies on the two most expressed fragile sites (FRA3B and FRA16D), implies a 
tumor suppressor function for the genes within the fragile sites and genetic alteration of FHIT 
and WWOX (FRA3B and FRA16D associated genes) has been frequently reported. (Giarnieri et 
al.; Lewandowska et al. 2009; Ludes-Meyers et al. 2009; Hassan et al. 2010). These findings 
indicate that at preliminary stages of tumor development, the altered expression of genes located 
at fragile sites maay elicit a cellular response against hazards. In addition, observation that CFSs 
and the large genes are evolutionary co-conserved further suggests that these genes and the 
unstable regions share some function within normal cells (Krummel et al. 2002).  
Herein, CFS genes CLNTLN and LINGO2, associated to FRA9G and FRA9C, respectively, were 
investigated in the context of genomic alterations on 9p in different tumors.  
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4.2 Fragile site genes; tumor-associated function 
 
4.2.1 FRA9G/CNTLN 
 
CNTLN gene which encodes for a centrosomal protein is located at FRA9G. Similar to many 
fragile site genes, it is a gene with very large introns. Centrosome abnormalities, which are also 
associated with high degree of aneuploidy, are prevalent in almost all types of solid tumors and 
certain cases of hematological cancers (D'Assoro et al. 2002; Fukasawa 2005).   
Recently, the rat protein of this gene has been isolated and shown to possess coiled-coil 
domains, but lack known functional domain (Makino et al. 2008). Their results indicated that 
centlein is a centrosomal protein in interphase and mitosis. They showed the expression of 
Centlein in various rat normal tissues and cell lines. CNTLN expression was also detected in 
HeLa cells. 
The aCGH results in this study showed FRA9G/CNTLN to be disturbed by rearrangements in 
seven cell lines (out of 29). Three of these cell lines were NB, including SK-N-BE(2)C, 
SK-N-FI and Vi-856. The whole region of the gene was heterozygously deleted in SK-N-FI and 
SK-N-BE(2)C. In Vi-856, the gene sequence was damaged by two breakpoints. In BC cells 
COLO-824 and MX-1, in spite of the amplification of the large parts of the 9p which spanned 
over the CNTLN/FRA9G region, breakages were observed exactly within the CNTLN locus 
which led to interstitial deletion of parts of the gene. These observations imply that deletions in 
CNTLN gene may be an advantage for tumor progression. Still, when the expression of CNTLN 
at RNA level was analyzed in COLO-824 and MX-1, one could detect CNTLN expression only 
in MX-1 cells. This suggests that alterations were probably heterozygous in MX-1 cell line. 
Moreover, in MFM-223 cells which did not present genetic alterations at FRA9G/CNTLN, no 
gene expression was detected. One could envisage an epigenetic inhabitation of expression via 
hypermethylation of CNTLN in MFM-223 cell line. 
One important observation regarding the deletions in CNTLN gene was that all the interstitial 
deletion occurred within the large introns. One hypothesis regarding the presence of large 
introns in CFS genes has suggested a regulatory role in gene expression and response to stress. 
A study looking for prostate cancer susceptibility alleles, localized on such allele within one of 
the large introns of FHIT gene. This atudy suggests that DNA changes within the sequence of 
such introns could dramatically impact the gene function. There are also studies indicating that 
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there are many more RNA species encoded within the genome than was predicted previously. 
Taken together, these studies further support the hypothesis that large introns within the CFS 
genes may be producing RNA species which function regulates gene expression. The results 
revealed in this study, show that introns of CNTLN gene are frequent targets for genomic 
deletions and therefore are also in favor of this hypothesis. 
A ubiquitous expression of CNTLN gene in all the 21 human normal tissues tested here was 
detected. This observation, given the differentiated expression of the gene observed in tumor 
cells, indicate an important function of the gene product in the biology of the cell and cancer 
development, which as far needs defined to be defined. 
 
 
4.2.2   FRA9C /LINGO2 
 
LINGO2 (leucin-rich repeat and Ig domain containing 2), located at FRA9C region, belongs to 
the LINGO/LERN gene family which is often expressed in the nervous system (Carim-Todd et 
al. 2003). Every member of this family has shown distinct patterns of expression in mouse 
embryos, as Lingo2/LERN3 expression has been seen in a population of cells lying adjacent to 
the epithelial lining of the alofactory pit (Haines and Rigby 2008). Unlike the expression of 
most of the LINGO/LERN genes that increases as the embryo develops and is low in the adult, 
LINGO2 has been detected in mouse adult brain (Haines and Rigby 2008) and appeared to be 
restricted to neural tissues. LINGO2 encodes a leucin-rich repeat (LRR) transmembrane protein, 
the function of which is unknown. Many examples of LRR proteins are found to be expressed in 
the nervous system. Duplications of LRRN6A, which maps to the centromeric end of a region of 
genomic instability at 15q24, have been defined as a susceptibility factor for panic and anxiety 
disorders (Gratacos et al. 2001). LERN1 (leucin-rich repeat neural protein 1) has similarity to 
the proteins involved in axional guidance and migration, nervous system development and 
regeneration. LINGO1 has recently been associated with an increased risk of essential tremor 
(ET) and Parkinson disease (PD) (Clark et al.; Haubenberger et al. 2009). LINGO2 is a less well 
characterized paralog of LINGO1 which is biologically a plausible candidate gene for 
neurodegenerative disease. Given the high degree of homology between LINGO1 and LINGO2 
protein (61%), LINGO2 has been suggested to be a reasonable candidate gene for ET and PD 
(Vilarino-Guell et al.).  
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Many of the large CFS genes are involved in neurological development. The first CFS gene 
identified in this regard was Parkin, which has shown to be mutated in some patients with 
autosomal recessive juvenile Parkinsonism. The PARK2 gene is among several other genes 
located at FRA6E (Denison et al. 2003). Spontaneous deletion of Parkin in mice results in the 
Quaker (viable) phenotype. Another CFS gene is GRID2 (delta2 glutamate receptor gene) that is 
located within FRA4F (Chauvet et al. 2004; Rozier et al. 2004).  Deletion of GRID2 in mice 
results in phenotype Lurcher, which is associated with ataxia. RORA, another large CFS gene, 
encodes an orphan retinoic receptor and is mapped to FRA15A. The gene product binds to the 
hypoxia inducible factor and therefore may be involved in cellular responses to stresses 
(Chauvet et al. 2004). A number of other large fragile site genes that appear to be significantly 
involved in neurological development are CNTNAP2/FRA7I (Verkerk et al. 2003), 
LRP1B/FRA2F (Cam et al. 2004) and IL1RAPL1/FRAXC (Zhang et al. 2004). 
In this study, a very limited expression of LINGO2 in human normal tissues, including brain, 
kidney, ovary, testes, prostate and placenta was detected. LINGO2 expression was observed, in 
accordance to few other reports, not only in a part of nervous system (brain), but also, in 
contrast to what was speculated in those studies, in a few number of other tissues.  
The aCGH data presented here show that that 6 out of 9 NB cell lines are damaged within or 
very close to their LINGO2/FRA9G locus. Moreover, in two BC cell lines, MX-1 and COLO-
824, interstitial deletions within the fragile site gene were detected. In total, one third of all the 
cell lines showed rearrangements in their LINGO2 locus. Four of the NB cells, including SH-
EP, Vi-856, SK-N-FI and Kelly, plus the two BC cell lines bore the deletions in their largest 
intron, 4-5. In LAN-6, the deletion was in the proximal vicinity of the gene and only 30 kb and 
50 kb downstream to mir-876 and mir-873, respectively. In SK-N-BE(2)C, in addition to an 
interstitial deletion particularly affecting the regulatory 5' upstream region of the gene, the 
whole LINGO2 sequence was heterozygously deleted. The brain cell line, U-138, showed a 
breakpoint within intron 3-4 of LINGO2. These findings indicate that LINGO2 locus is 
frequently affected by rearrangements in cancer cells, especially in NB. The observation that the 
majority of the genetic alterations in LINGO2 gene happen within the large introns, is a strong 
support for the regulatory role of the large introns in CFS genes that has been also proposed by 
some other studies. It is also suggested that the instability-induced alterations in some CFS 
genes contribute to cancer development, in a two step process. First the initial alterations occur 
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primarily within intronic regions (as these genes are greater than 99% intronic). Then these 
alterations, which are not benign, alter the repertoire of transcripts produced from these genes 
(Smith DI 2006). 
Here, the expression analysis of LINGO2 gene at RNA level in NB and glioma/GB cell lines 
presented a differential expression pattern. Twenty five NB cells show a very differential pattern 
of expression for LINGO2. In more than half of the cell lines LINGO2 was not detected at RNA 
level. From 10 cell lines showing LINGO2 expression, 8 were MYCN amplified. The MYCN 
gene is a proto-oncogene and belongs to the MYC family of transcription factors. Among the 
prognostic indicators of NB, MYCN amplification has been associated to poor prognosis. 
However, the significance of MYCN expression in the clinical and biological behavior of 
neuroblastoma is still not clear. Whether the co-existence of MYCN amplification and LINGO2 
expression in NB is a cause and effect or just two parallel pathways during the pathogenesis of 
neuroblastoma, needs to be further investigated. This would allow us to have a better 
understanding of the biological function of the LINGO2 gene. 
In two brain cell lines, U-138 and Hs-683, lack of LINGO2 expression showed to be the result 
of two different mechanisms, chromosomal deletion and hypermethylation inhibition.  
Hemi- and Homozygous deletions of fragile site gene FHIT have been frequently reported in 
various cancers (Fong et al. 1997; Sozzi et al. 1997; Wistuba et al. 1997). Also, several studies 
demonstrating the absence of point mutations in two common fragile site genes, WWOX and 
FHIT, have suggested that other mechanisms, in addition to deletions, regulate their expression. 
A recent study showed promoter hypermethylation as a critical regulator of FHIT expression in 
lung cell lines (Verri et al. 2009). A similar result has been shown to exist for WWOX gene 
expression in pancreatic cancer cell lines (Kuroki et al. 2004). Due to high frequency of 
methylation events in FHIT and WWOX in association with loss of expression, it is suggested 
that CFS genes could enrich a hypermethylation panel for various types of cancer. Recent data 
concerning lung carcinogenesis indicates that extensive DNA damage through double strand 
breaks could in part be responsible for the acquisition of aberrant promoter hypermethylation. It 
has been suggested for FHIT gene that both deletions and methylation events are two 
independent factors that contribute to functional loss of expression (Verri et al. 2009).  
Further studies on expressional pattern of LINGO2 in cancer and modes of expression inhibition 
of this CFS gene could further shed light on its possible role in carcinogenesis. 
 83
 
Discussion
 
 
 
4.3   Non-fragile site genes located at unstable regions of 9p 
 
In addition to common fragile site genes, CNTLN and LINGO2, there are several other genes 
located on the three localized clusters of breakpoints which are revealed from the results of this 
study. 
According to literature, CDKN2A/p16 is considered to be the main target for 9p rearrangements 
in tumors. LOH, as well as point mutations and hypermethylation have been described as 
inactivation mechanisms for CDKN2A. Mcdermott and colleagues (McDermott et al. 2006) 
showed that lack of p16 protein specifically leads to disturbance of centrosome function. In fact, 
there are several oncogenic and tumor-suppressor proteins which have been found to be 
involved in the regulation of centrosome function and duplication. When those proteins are 
damaged, it results in mitotic defects that are associated with numeral and functional 
abnormalities of centrosomes. The most frequently damaged region revealed by our array 
experiments was 9p21.3. In addition to CDKN2A, there were few other genes that present 
relatively high degree of genomic alterations, including MTAP, ELAVL2 and IFN gene clusters.  
MTAP gene (methylthioadenosin phosphorylase) resides approximately 100 kb from CDKN2A 
and is reported to be frequently co-deleted with it. It encodes a ubiquitous enzyme which is 
essential in methionine and purine metabolism and is frequently deficient in cancer cell lines 
and some malignancies (Kamatani et al. 1981; Schmid et al. 1998; Garcia-Castellano et al. 
2002). 
ELAVL2 (embryonic lethal, abnormal vision, Drosophila-like 2) resides approximately 2 Mb 
proximal to CDKN2A and encodes for a neural-specific RNA-binding protein. It is a regulator of 
MYCN expression in neuroblastoma and is involved in neural differentiation (Chagnovich and 
Cohn 1996; Chagnovich et al. 1996; Ball and King 1997). Co-deletion of ELAVL2 with MTAP 
and CDKN2A genes has also been observed (Kamath et al. 2008).  
The IFN gene cluster resides 500-1000 kb, telomeric to CDKN2A. This cluster contains IFN-β 
and almost 25 genes and pseudogenes for IFN-α and IFN-γ. Frequent homozygotic deletions of 
IFN-α and IFN-β have been observed and their loss sensitisez cells to the growth inhibitory 
actions of exogenous IFNs (Haus 2000). Deletions of the IFN gene cluster have been reported in 
glioma cell lines (James et al. 1993), lung cancer (Olopade et al. 1993), head and neck cancer 
(Lydiatt et al. 1998), and leukemias (Usvasalo et al.). IFN gene cluster also have been 
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demonstrated to be deleted in whole or in part in more than half of the CDKN2A-deficient cell 
lines (Zhang et al. 1996). 
In the more telomeric cluster, where FRA9G/CNTLN is located, there are two neighboring genes 
to CNTLN, including BNC2 and SH3GL2. BNC2 encodes for basonuclin2 which is a recently 
discovered zinc-finger protein which is highly expressed in normal keratinocytes, ovary, testes, 
kidney and lung, however it is present in virtually every cell type. It is mostly localized in the 
nucleus and is likely related to mRNA splicing processes and in general is suggested to function 
as a transcriptional regulator (Romano et al. 2004; Vanhoutteghem and Djian 2006). One 
interesting observation about this gene is that it has the potential to generate 90,000 mRNA 
isoforms encoding more than 2000 different proteins. In fact, there are few genes known to 
generate such extraordinary number of splicing isoforms. There are two recent studies implying 
BNC2 as a tumor-associated gene. First, which reported the homozygous deletion spanning 
9p22.3-p22.2 (region where harbors BNC2 gene) and the decreased expression of BNC2 mRNA 
in Barett's esophagus (BE) carcinoma (Akagi et al. 2009). Second, the study by Song et al, 
which reported that SNP microarray analysis in ovarian cancer revealed a cluster of frequent 
SNPs on 9p22.2, nearby BNC2 gene (Song et al. 2009). 
SH3GL2 (SH3-domain GRB2-like 2), the other neighboring gene to CNTLN, encodes for an 
evolutionary conserved amino acid domain protein involved in signal transduction, mobility, 
enzymatic activation and transcriptional regulation. This gene is predominantly expressed in the 
brain (Giachino et al. 1997) and is suggested to be a candidate tumor suppressor gene. Frequent 
deletion and abnormalities of SH3GL2 have been associated to development of breast carcinoma 
(Sinha et al. 2008), dysplastic lesions of head and neck carcinoma (Ghosh et al. 2009), laryngeal 
carcinoma (Shang et al. 2007) and gastric cancer (Sun et al. 2006).  
The aCGH results also revealed a cluster of breakpoints localized at 9p22.2, a region that spans 
over BNC2, CNTLN and SH3GL2 genes. Three NB, two brain and one CC cell lines showed 
deletion within BNC2 gene. SH3GL2 gene presented breakages within two NB cell lines.  
The 9p22.2 region has been frequently demonstrated to be the target for chromosomal deletions 
in various cancers. The observation in this study, which is in line with the results of other 
studies, suggests an important function of the genes located in this region in tumor biogenesis. 
Since almost all of these genes in the instability area are related to normal and malignant 
function of different cell types, one can assume that they are actively transcribed. This predicts 
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an open chromatin structure for these regions in order to be accessible to transcription factors 
and gene expression control. The open configuration of chromatin structure have been proposed 
to be predisposed to double strand breaks, which have been reported to be the main reason for 
DNA instabilities. 
 
Several studies have shown that miRNAs play an important role in certain human cancers, 
including B cell chronic lymphocytic leukemias (Calin et al. 2002), and Burkitts lymphoma, 
colon cancer, lung cancer, and breast cancer (Esquela-Kerscher and Slack 2006; Sevignani et al. 
2006). Furthermore, miRNAs can downregulate a large number of target mRNAs and since 
many of these targets are either tumor oncogenes or tumor suppressors, it is suggested that 
miRNAs can influence susceptibility and predispose individuals to different cancers. It has been 
reported that more than 50% of miRNA genes are located in cancer-associated genomic regions 
and fragile sites, as well as in minimal regions of LOH and minimal regions of amplification 
(minimal amplicons) (Calin et al. 2004). 
Five miRNA genes are located on the short arm of chromosome 9. Two of them, mir-873 and  
mir-876 are located on very close centromeric side of FRA9C/LINGO2 locus. The other two, 
including mir-31 and mir-491 are located on the vicinity of distal CDKN2A. The fifth one which 
is mir-101-2 is located on distal end of 9p arm. Therefore, four out of five miRNA genes on 9p 
are located close to the two clusters of breakpoints earlier identified by aCGH results.  
 
 
4.3 Sequence analysis of the breakpoint-clustering regions on 9p 
 
Unlike rare fragile sites which CGG tinucleotide repeats expansion and AT-rich minisatellite 
repeats are described as molecular basis for their instability, there is not a consensus agreement 
on a common molecular feature shared by common fragile sites that could lead to their fragility. 
Common fragile sites are relatively AT-rich sequences and do not contain any expanded repeats 
or specific sequences. Moreover, comparison of different common fragile sites, including 
FRA9C, FRA9G, FRA3B, FRA16D, FRA13A and FRA1E,  show a considerable variation in 
DNA repeat sequences, in particular LINE1 elements (Sawinska et al. 2007). This observation is 
in contrast to what has been proposed for FRA3B, in which LINE1 elements are considered to 
have a probable major role in the DNA instability at the fragile locus. Only FRA9G seems to 
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have a slightly higher degree of LINE1 elements. The same results were obtained when the three 
regions of breakpoint-clustering on 9p were analyzed for their DNA repeat elements. No 
significant differences were observed between the DNA sequence of the three regions of clusters 
and that of non-fragile genome. Only in the core region of FRA9G breakpoint clusters, within a 
part that the majority of the breakpoint occurred in, a relatively high number of LINE1 elements 
were presented. This might suggest an involvement of LINE1 elements in FRA9G region 
instability. One could not imply this for the other two unstable clusters. 
El Achkar and colleagues showed that the majority of common fragile sites are located at the 
interface of G/R boundaries of chromosome (El Achkar et al. 2005). G-bands are AT-rich and 
gene-poor and undergo DNA replication late in the S phase of the cell cycle. R-bands are CG-
rich and gene-rich and undergo replication early in the S phase. R- and G-bands are different in 
their structure and function. The DNA replication kinetic at the R-band/G- band transition is still 
unknown but it is likely that these regions are difficult to duplicate and particularly sensitive to 
treatments that disturb the replication, leading to fragility.  
A study by Mishmar et al, identified enrichment of clusters of DNA sequences with high 
flexibility, termed "flexibility peaks", in the FRA7H sequence (Mishmar et al. 1998). These are 
short regions of a few hundred nucleotides that show high local variation in twist angle, which 
may affect chromatin condensation and fragility. Since then, some other studies have shown 
high frequency of these regions in common fragile sites. As it has been shown by Zlotorynski et 
al, aphidicolin-induced fragile sites mapped to G band, perform an average of 5.7 flexibility 
islands per 100 kb (Zlotorynski et al. 2003). Very recently, in a model proposing mechanisms 
underlying instability at two common fragile sites, it was speculated that the breakpoint-
clustering regions at common fragile sites is flanked by the high-flexibility peaks and the R/G 
band boundaries.  
In the present study, analyzing FRA9C and CDKN2A regions of instability revealed an average 
of 8 flexibility peaks per 100 kb. This is slightly higher than what is proposed for aphidicolin-
induced fragile sites. FRA9G region, as an aphidicolin-induced FS, showed even lower number 
of peaks than the average 3.5 peaks/100 kb. 
The sequences enriched with AT-dinucleotide-rich stretches are potentially capable of forming 
secondary structure and therefore causing replication fork collapse and double strand breaks (Le 
Beau et al. 1998; Hellman et al. 2000; Palakodeti et al. 2004; El Achkar et al. 2005). In a study 
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by Zhang and colleagues, it was demonstrated that sequences enriched in perfect polymorphic 
AT repeats within FRA16D, can efficiently cause stalling of replication fork, and this is directly 
dependent on the length of an AT repeat (Zhang 2007). However, it still remains to be 
elucidated whether these motifs have crucial role in CFS stability and if this could be the case 
for the other CFSs. It has been proposed that expanded perfect AT-rich repeats, which are prone 
to form hairpin or cruciform structures (non-B DNA forms), can stall a replication fork 
(Mangelsdorf M. 1997; Hewett et al. 1998). In addition, the binding of ligands for AT-rich 
DNA minor groove, or interrupting replication compelled by incorporation of BrdU, which 
replaces thymidine in such highly AT-rich sequences, may lead to hindering of chromosome 
condensation. Failure of chromosome condensation might generate unstable chromatin in this 
region and be expressed as gaps or breaks in metaphase chromosomes.  
Altogether, based on the results in this study, DNA sequence analysis in terms of DNA repeats 
elements did not reveal any specific feature element as an important factor undertaking the 
fragility in any of the three breakpoint-clustering regions on 9p. However, regarding flexibility 
peaks, clusters in the region spanning FRA9C and CDKN2A presented a higher number of peaks 
in comparison to FRA9G and human genome. This suggests firstly that the twist angle of DNA 
in FRA9C and CDKN2A loci could partly be of some importance for breakages occurring within 
them, and secondly that probably no common DNA feature is shared by CFSs and regions of 
high instability in the genome as a cause for their fragility. 
 
 
 
4.5    Conclusions and Perspective 
 
Here, 9p instability in four tumor models was investigated by using high-resolution array CGH. 
Then the results obtained from aCGH were then confirmed using FISH experiments.  
The results clearly showed frequent 9p rearrangements in more than 70% of the cell lines. The 
size, localization and number of breakpoint throughout the entire 9p were precisely determined 
and the results presented various pattern of 9p instability in different tumor types. Overall, three 
clusters of localized breakpoints were identified on 9p, including FRA9G/CNTLN, CDKN2A and 
FRA9C/LINGO2. The percentage of rearrangements observed in these three clusters in all the 
examined cell lines was 26% (FRA9G/CNTLN), 50% (CDKN2A) and 40% (FRA9C/LINGO). 
CDKN2A is a commonly known tumor suppressor gene which has been frequently reported to 
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be deleted in cancer. Based on the results of this study, the two common fragile sites and their 
associated genes, FRA9G/CNTLN and FRA9C/LINGO, are proposed to be new candidates of 
tumor-susceptibility loci. In addition, high-resolution aCGH allowed detecting recurrent 
damages in several genes in different tumor models. These genes included BNC2 and SH3GL2 
(in NB), ELAVL2 (in glioma/GB) and MTAP and IFN gene cluster (in glioma/GB, NB and CC). 
This finding is in agreement with previous studies which have proposed these genes to be 
associated with different cancer types. 
There were miRNA clusters close to FRA9C (mir-873 and mir-876) and CDKN2A region (mir-
31 and mir-491), which is in accordance to the finding that miRNA clusters mostly reside at 
tumor-susceptibility chromosome areas.  
Moreover, LINGO2 expression analysis in this study indicated hypermethylation as an 
inhibitory mechanism for expression of the gene in certain cells. It has been suggested that 
hypermethylation can trigger chromosomal instability. 
In the quest to identify novel candidates for genomic instabilities in cancer, one important task 
would be to investigate the dysfunctions in these novel tumor-associated genes genes and also to 
explore the causes and impacts of such abnormal functions in the process of tumor development. 
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